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ABSTRACT 
Growth factors can regulate a variety of cellular processes by activating receptors on the 
cell surface. Many of the receptors belong to the receptor tyrosine kinase family, including the 
platelet-derived growth factor receptor and the epidermal growth factor receptor and its related 
family members, such as ErbB2. Constitutively activated receptor tyrosine kinases and their 
downstream signaling pathways (such as the Ras-mitogen activated protein kinase pathway and 
the phosphatidylinositol 3 kinase-Akt pathway) are frequently observed in cancer cells. 
Therefore, understanding the degradation mechanism of receptors is important and may 
facilitate the development of new prognostic or treatment strategies for cancer. Ankyrin105 is 
the smaller isoform of ankyrin3 and is localized to late endosomes and lysosomes. Our 
laboratory has previously shown that ankyrin105 can bind to the phosphatidylinositol 3 kinase 
regulatory subunit p85, stimulate lysosomal-mediated degradation of the platelet-derived 
growth factor receptor and differentially affect its signaling pathways in NIH 3T3 cells. To 
determine whether ankyrin105 can induce degradation of multiple receptor tyrosine kinases in a 
similar manner, we extended these studies to include the epidermal growth factor receptor and 
its downstream signaling in this project. Hemagglutinin-tagged ankyrin105 was introduced into 
COS-1, HEK293T, MCF10A, MDA-MB-231 and AU565 cells, respectively. We demonstrated 
that overexpression of ankyrin105 did not enhance the epidermal growth factor receptor 
degradation or downregulation of its signaling pathways in these selected cell lines. AU565 
cells, which expressed relatively high levels of both epidermal growth factor receptor and 
ErbB2, were susceptible to geldanamycin or herceptin facilitated ErbB2 internalization and 
degradation, which subsequently promoted the epidermal growth factor receptor degradation. 
However, ankyrin105 did not further improve geldanamycin-induced epidermal growth factor 
receptor degradation or impact its downstream signaling pathways. These studies suggest that 
the influence of ankyrin105 may be receptor-specific (platelet-derived growth factor receptor, 
but not epidermal growth factor receptor) and/or cell type specific (NIH 3T3 cells, but not 
COS-1, HEK293T, MCF10A, MDA-MB-231 or AU565 cells). 
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1.0 INTRODUCTION 
1.1 Overview of Signal Transduction 
Signal transduction is a process that whereby extracellular signaling molecules activate 
specific receptors, leading to the transmission of signals into the cell and the regulation of 
cellular processes. It can regulate gene expression, enzyme activity, metabolism and many other 
processes. The signaling molecules participate in most cellular functions and are thus 
responsible for physiological changes in the organism. Defects in signal transduction may result 
in cancers and other diseases. 
Most extracellular signaling molecules are not able to transit across the cell membrane 
directly because of their large size and hydrophilic polarity (Berg et al., 2002). So 
membrane-associated receptors act as intermediates for signal transduction. When an 
extracellular signaling molecule targets to its receptor on the cell surface, the receptor recruits a 
variety of intracellular molecules to complete this process. Many of the receptors are 
transmembrane proteins, such as receptor tyrosine kinases (RTKs), G protein coupled receptors 
(GPCRs), integrins and toll-like receptors (TLRs) (Berg et al., 2002). Among these receptors, 
RTKs are related to this project. 
The extracellular domain of RTKs recognizes and binds to the extracellular growth factors 
and then the intracellular domain is activated. Protein phosphorylation cascades are carried out 
to transfer the signal inside cells and regulate cellular processes. They are involved in several 
signaling pathways, including the Ras-mitogen activated protein kinase (MAPK) pathway, the 
phosphatidylinositol 3 kinase (PI3K)-Akt pathway, the phospholipase C γ (PLC γ) pathway, the 
Janus kinase (JAK)-signal transducers and activators of transcription (STATs) pathway (Biarc et 
al., 2011; Dengjel et al., 2009; Madhani, 2001). 
Since continuously activated RTKs and signaling pathways are correlated with 
abnormalities in cells, the signal transduction needs to be terminated soon after activation. 
Therefore, the downregulation mechanism of RTKs is important. Activated RTKs are rapidly 
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endocytosed mainly via a clathrin-dependent or a clathrin-independent manner (Mousavi et al., 
2004; Mukherjee et al., 1997). Many of the receptors are dephosphorylated and recycled back 
to the cell surface. Only a small fraction of receptors may divert to lysosomes for degradation 
(Sorkin and Von Zastrow, 2002). 
1.2 Receptor Tyrosine Kinases 
Growth factors can control a variety of cellular processes by activating corresponding 
receptors on the cell surface. They are very important in regulating cell growth, cell cycle 
control, metabolism, proliferation, differentiation, maturation, survival and migration (Bache et 
al., 2004; Lemmon and Schlessinger, 2010). Most of them are proteins or steroid hormones. 
Growth factor are divided into many classes, including epidermal growth factor (EGF), 
platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), hepatocyte growth 
factor (HGF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), insulin, 
insulin-like growth factor (IGF) and ephrin (Aaronson, 1991). 
Many of the growth factor receptors belong to the RTK family. Fifty eight RTKs have 
been identified in the human genome (Robinson et al., 2000). RTKs are composed of an 
N-terminal extracellular ligand-binding domain, a single transmembrane domain and a highly 
conserved C-terminal cytoplasmic tyrosine kinase domain (Biarc et al., 2011; Cowan-Jacob, 
2006; Li and Hristova, 2010; Takeuchi and Ito, 2011). According to the binding ligand and 
specific structural differences, RTKs can be divided into 20 subfamilies. These include 
epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), 
fibroblast growth factor receptor (FGFR), hepatocyte growth factor receptor (HGFR), nerve 
growth factor receptor (NGFR), vascular endothelial growth factor receptor (VEGFR), insulin 
receptor (IR), insulin-like growth factor receptor (IGFR) and ephrin receptor (EPHR). The 
structures of these members differ by their extracellular and tyrosine kinase domains (Figure 
1.1) (Aaronson, 2005; Blume-Jensen and Hunter, 2001; Lemmon and Schlessinger, 2010; 
Robertson et al., 2000). 
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Figure 1.1 The structures of major members of different receptor tyrosine kinase families. 
RTKs are composed of an N-terminal extracellular ligand-binding domain, a single 
transmembrane domain and a C-terminal cytoplasmic tyrosine kinase domain. The structures of 
these members are different within the extracellular and tyrosine kinase domains. The 
extracellular domain of EGFR, IR, IGFR and EPHR has one or two cysteine-rich domains and 
the extracellular domain of PDGFR, FGFR, NGFR, VEGFR and EPHR has one or more 
immunoglobulin-like domains. The tyrosine kinase domain of PDGFR, FGFR, NGFR and 
VEGFR is divided by a non-catalytic kinase insert domain. The figure is modified from 
Blume-Jensen and Hunter, 2001 and Lemmon and Schlessinger, 2010. 
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Growth factors and RTKs are essential for signal transduction inside cells. Extracellular 
signals (growth factors) can trigger a series of intracellular signaling pathways via the 
transmembrane receptors (RTKs). Multiple RTKs share a similar mechanism to be activated 
and then activate downstream signaling pathways. An “open-closed” switch mechanism has 
been demonstrated in EGFR and FGFR (Burgess et al., 2003; Olsen et al., 2004). The 
extracellular domain is inactive without growth factors, which suggests a “closed” state. When 
ligands (growth factors) bind to the extracellular domain of RTKs, the dimerization region 
within the extracellular domain is exposed and the receptor dimerizes with the neighboring 
receptor, which is referred as the “open” state (Bae and Schlessinger, 2010; Burgess et al., 2003; 
Li and Hristova, 2006; Olsen et al., 2004). In summary, ligand docking regulates the RTK 
equilibrium between “open” and “closed” state. Ligand binding causes a conformational change 
of the extracellular domain and dimer formation. However, there are some exceptions. ErbB2, 
which is from the EGFR subfamily, has a constitutively exposed dimerization arm and thus it is 
able to form dimers with its subfamily members in the absence of growth factors (Burgess et al., 
2003). IR or IGFR is a constitutive dimer, linked by disulfide bonds, and ligand binding 
activates the tyrosine kinase (Ottensmeyer et al., 2000). In some studies, the transmembrane 
domain also contributes to the dimerization in EGFR and FGFR (Li et al., 2005; Mendrola et 
al., 2002). In an unstimulated RTK, an activation loop blocks the tyrosine kinase domain in the 
cytoplasm from its potential substrates. Upon ligand docking, the tyrosine residues in the 
activation loop are autophosphorylated by its own tyrosine kinase domain due to the adjacent 
dimeric receptor (Hubbard and Till, 2000). The phosphorylation of the activation loop releases 
itself from the tyrosine kinase domain and stabilizes its own conformation. This fully activated 
receptor then phosphorylates additional tyrosine residues within the intracellular domain (Bae 
and Schlessinger, 2010; Blume-Jensen and Hunter, 2001; Robertson et al., 2000). This provides 
several binding sites for many intracellular signaling molecules and some are phosphorylated 
by the receptor. The binding of signaling molecules to the receptor phosphotyrosine sites is 
usually via Src homology-2 (SH2) domain or phosphotyrosine-binding (PTB) domain in the 
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signaling proteins (Zhou, 2005). Downstream signaling pathways are then activated, such as the 
Ras-MAPK pathway and the PI3K-Akt pathway as described in section 1.3 (Biarc et al., 2011; 
Dengjel et al., 2009). 
Mutation and deregulation of RTKs are usually correlated to a variety of human 
syndromes and diseases, including cancers (Aaronson, 1991; Lemmon and Schlessinger, 2010; 
Robertson et al., 2000). For example, mutations in IR may result in type A insulin resistance 
(Ottensmeyer et al., 2000) and mutations in FGFR may cause Dwarfism syndromes (Webster 
and Donoghue, 1997). Overexpression and defective downregulation of EGFR have been 
linked to several cancers, such as breast cancer, colorectal carcinoma, lung cancer and brain 
tumors (Klapper et al., 2000; Yarden and Sliwkowski, 2001). Mutations in the extracellular 
domain and the tyrosine kinase domain, directly affect RTK signaling. Whereas, it has been 
demonstrated that mutations in the transmembrane domain also plays a critical role in RTK 
function. They may impact ligand binding, receptor dimerization, the structure of the tyrosine 
kinase domain and downregulation of activated RTK (Li and Hristova, 2010). Therefore, RTKs 
are used as useful targets for drug research and development for the treatment of cancers and 
other RTK related diseases (Takeuchi and Ito, 2011; Wieduwilt and Moasser, 2008). 
1.2.1 Epidermal Growth Factor Receptor 
     The EGFR subfamily is the most well studied among RTK families and it contains 4 
members: EGFR (ErbB1 or HER1), ErbB2 (HER2 or Neu), ErbB3 (HER3) and ErbB4 (HER4) 
(Burgess, 2008). They can regulate embryonic development, cell lineage determination, tissue 
repair and cancer. The EGFR subfamily was the first discovered RTK in cancer and the 
members are the most studied receptors for understanding carcinogenic mechanism (Burgess, 
2008; Eccles, 2011; Pinkas-Kramarski et al., 1997). 
    The EGFR is activated by the dimerization of its family members via ligand binding. They 
can form both homodimers and heterodimers with different family members. At least 13 ligands 
have been discovered (Yarden, 2001). EGFR and ErbB4 have a number of ligands, while no 
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ligand is found to bind to ErbB2 (Citri et al., 2003). EGF, transforming growth factor-α 
(TGF-α), heparin binding EGF-like growth factor (HB-EGF), amphiregulin (AR), betacellulin 
(BTC), epigen and epiregulin (EPR) are EGFR ligands. ErbB3 only has 3 ligands: neuregulin 
(NRG) 1, NRG 2 and heregulin (HRG). ErbB4 ligands include HB-EGF, BTC, EPR, 
tomoregulin (TR), NRG 1, NRG 2, NRG 3, NRG 4 and HRG. All of these growth factors have a 
common EGF motif, which consists of 6 cysteine residues including 3 intramolecular disulfide 
bonds. This motif plays a key role in ligand binding. These ligands are present as type I 
transmembrane proteins, and mature growth factors are generated by enzyme cleavage at the 
cell surface (Berasain et al., 2007; Harris et al., 2003; Ogiso et al., 2002). 
Like other RTKs, EGFR members share a similar basic structure: an extracellular 
ligand-binding domain (about 620 residues), a hydrophobic transmembrane domain (about 23 
residues) and a highly conserved cytoplasmic tyrosine kinase domain (about 260 residues). 
There is a C-terminal regulatory region (about 232 residues) containing multiple tyrosine 
residues preceded by the kinase domain (Figure 1.2) (Burgess et al., 2003). The extracellular 
region is highly glycosylated (Zhen et al., 2003) and has 4 distinct subdomains: 2 homologous 
large domains (domain I or L1 and III or L2) that contain leucine-rich repeats and 2 
cysteine-rich domains (domain II or S1 and IV or S2) that may have several disulfide-bonded 
modules (Figure 1.3 A). A crystal structure study shows the EGF-EGFR and EGFR-EGFR 
interactions, which reveals the dimerization mechanism of EGFR (Figure 1.4) (Ogiso et al., 
2002). One EGF molecule binds to one EGFR molecule and then two 1:1 EGF-EGFR 
complexes form a dimer. The ligand binding region is between domains I and III. Domain II is 
characterized as the dimerization arm, which is a unique feature for EGFR subfamily. The 
conformational change after ligand docking breaks the link between domains II and IV, exposes 
the dimerization arm, and then induces dimerization (Figure 1.3 B) (Burgess et al., 2003; Ogiso 
et al., 2002). 
The intracellular tyrosine kinase domain is functionally inactive when the receptor is still a 
monomer. Since homodimers or heterodimers are formed upon ligand stimulation, the adjacent 
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Figure 1.2 The domain structure of EGFR subfamily. There are 3 major domains: an 
extracellular domain, a transmembrane domain and a cytoplasmic tyrosine kinase domain. The 
extracellular domain has 4 distinct subdomains: domain I, II, III and IV. The intracellular 
tyrosine kinase domain is between the juxtamembrane region and C-terminal regulatory region 
containing 6 tyrosine residues that can be phosphorylated. The figure is modified from Bazley 
and Gullick, 2005 and Burgess et al., 2003. 
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Figure 1.3 Growth factors induce activation of EGFR. A, Domains II and IV are linked to 
each other and the tyrosine kinase domain is inactive before ligand binding. B, The 
conformational change after ligand docking breaks domains II and IV link, exposes the 
dimerization arm in domain II and then induces dimerization. C, The dimerization promotes the 
autophosphorylation of activation loop. The phosphorylation of the activation loop releases 
itself from the tyrosine kinase domain and stabilizes its own conformation, and facilitates 
phosphorylation of tyrosine residues within the intracellular domain. The figure is modified 
from Mpofu, 2010 and Burgess et al., 2003. 
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Figure 1.4 The crystal structure of EGF-EGFR complex. The original structure data of 
EGF-EGFR complex was obtained from Protein Data Bank accession number 1IVO (Ogiso et 
al., 2002). The ribbon diagram was developed using PyMOL software (version 1.4.1). EGF and 
the extracellular subdomains I, II, III and IV of EGFR were labeled in different colors. 
EGF-EGFR and EGFR-EGFR interactions are shown. The EGF binding region is between 
domains I and III of the receptor. Domain II plays a role in EGFR dimerization. 
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2 tyrosine kinase domains promote the autophosphorylation of the activation loop and thereby 
activate the intrinsic catalytic activity of the tyrosine kinase domain (Bazley and Gullick, 2005; 
Fuller et al., 2008; Hubbard and Till, 2000). Some tyrosine residues within the regulatory 
region are then phosphorylated (Figure 1.2 and Figure 1.3 C). Every EGFR subfamily member 
has its own phosphotyrosine profile, which dictates the different downstream signaling 
molecules recruited (Pedersen et al., 2009). In addition, there is a juxtamembrane region (about 
40 residues) between the transmembrane and the intracellular domains (Figure 1.2) (Burgess et 
al., 2003). It can autoinhibit the tyrosine kinase activity and negatively regulate tyrosine 
phosphorylation (Hubbard, 2004). 
EGFR, the first identified and widely expressed member in this subfamily, is a 180 kDa 
glycoprotein. It was shown that all other EGFR subfamily members evolved from the EGFR 
(Sithanandam and Anderson, 2008). Normally, EGFRs are rapidly internalized and endocytosed 
once activated (Pedersen et al., 2009). Overexpression of EGFR impairs this downregulation 
process (Worthylake et al., 1999). Therefore, mutations and upregulation of EGFR may 
contribute to tumorigenesis. 
ErbB2 is a unique member in several aspects. First of all, no known ligand has been 
identified that can bind to ErbB2. Secondly, the extended structure of extracellular domain 
constitutively exposes the dimerization arm, so ErbB2 can form dimers without ligand docking. 
ErbB2 may be constitutively activated or be activated by dimerization. Thirdly, ErbB2 is a 
potential heterodimerization partner and ErbB2 overexpression may promote 
heterodimerization with other EGFR subfamily members because no ligand is required. Some 
studies suggest that there is a preference for forming heterodimers rather than homodimers for 
ErbB2, and the ErbB2-ErbB3 heterodimer is the most widely represented and most active 
(Burgess et al., 2003; Citri et al., 2003; Fuller et al., 2008; Yarden and Sliwkowski, 2001). 
Furthermore, ErbB2 is internalization resistant, and thus the heterodimers containing ErbB2 are 
very stable and their endocytosis is inhibited, which indicates that the downstream signaling is 
prolonged (Pedersen et al., 2009). ErbB2 can also enhance the binding affinity of the ligand to 
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its dimeric receptor (Fuller et al., 2008). Therefore, overexpression of ErbB2 is detrimental for 
cells and normally linked to cancers (Yarden and Sliwkowski, 2001). It has been shown that 
about 20% to 30% of breast cancer results from ErbB2 overexpression (Pedersen et al., 2008). 
ErbB3 can bind to its ligands but does not have tyrosine kinase activity due to the absence 
of some critical residues in its intracellular domain. However, the tyrosine residues in the 
regulatory region can still be phosphorylated and downstream signaling pathways can be 
triggered via the dimeric partner receptor in the ErbB3 heterodimer or by other kinases (Citri et 
al., 2003; Fuller et al., 2008). 
ErbB4 is the most related member to EGFR and is also fully functional (Wieduwilt and 
Moasser, 2008). Only ErbB4 has different isoforms and these isoforms are tissue specific 
(Veikkolainen et al., 2011) and critical in cardiovascular and neural development (Junttila et al., 
2000). 
1.2.2 Platelet-Derived Growth Factor Receptor 
PDGFR subfamily has 2 members: PDGFR α (170 kDa) and PDGFR β (190 kDa) 
(Claesson-Welsh, 1994). They have the RTK structural backbone and can homodimerize or 
heterodimerize with each other. The extracellular domain consists of 5 immunoglobulin-like 
domains and the first 3 domains are involved in ligand binding. However, domain 2 seems to 
play the most important role in binding. Domain 4 may help stabilize the PDGFR dimer 
(Heldin and Westermark, 1999). There is about 31% identity in the PDGFR α and PDGFR β 
ligand-binding domain. The tyrosine kinase domain is divided by a kinase insert domain in 
cytoplasmic region. This insert domain does not have catalytic activity. Multiple tyrosine 
residues that can be phosphorylated reside in juxtamembrane region, kinase insert domain and 
regulatory region (Figure 1.5) (Grimminger and Schermuly, 2010; Jones and Cross, 2004; Yu et 
al., 2003). 
The PDGF family, the PDGFR ligand, has 4 different peptide chains (PDGF-A, PDGF-B, 
PDGF-C and PDGF-D) encoded by 4 distinct genes (Tallquist and Kazlauskas, 2004). They all 
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Figure 1.5 The domain structures of PDGFR α and PDGFR β. The extracellular domain 
consists of 5 immunoglobulin-like domains. The cytoplasmic region has a split kinase domain 
interrupted by a kinase insert domain. There are multiple tyrosine residues that can be 
phosphorylated in the juxtamembrane region, kinase insert domain and regulatory region. The 
figure is modified from Chamberlain, 2007 and Jones and Cross, 2004. 
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function as dimers, and a dimer can bind to and activate 2 PDGFRs simultaneously (Heldin and 
Westermark, 1999). Compared to PDGF-A and PDGF-B, PDGF-C and PDGF-D are recently 
discovered and have a unique N-terminal C1r/C1s, urchin EGF-like protein and bone 
morphogenic protein 1 (CUB) domain other than the common growth factor domain. Five 
homodimers or heterodimers are formed within these isoforms by a disulfide bond. PDGF-A 
and PDGF-B can both homodimerize (PDGF-AA and PDGF-BB) and heterodimerize 
(PDGF-AB) with each other, but PDGF-C and PDGF-D can only form homodimers (PDGF-CC 
and PDGF-DD) (Reigstad et al., 2005). PDGF-AA, PDGF-AB, PDGF-BB and PDGF-CC can 
stimulate PDGFR α, whereas PDGF-BB and PDGF-DD can activate PDGFR β. In addition, 
PDGF-AB, PDGF-BB and PDGF-CC can bind to and then activate PDGFR αβ heterodimers 
(Board and Jayson, 2005; Claesson-Welsh, 1996; Fredriksson et al., 2004). 
When PDGF binds to the extracellular domain of PDGFRs, receptors dimerize and cause 
conformational change. The following steps are the same as for other RTKs: tyrosine kinase 
activation and receptor autophosphorylation. Phosphotyrosines are the binding sites for many 
intracellular signaling proteins containing SH2 and PTB domains. Thus, downstream signaling 
pathways are activated (Claesson-Welsh, 1994; Grimminger and Schermuly, 2010; Jones and 
Cross, 2004). 
PDGFR can control embryonic development, cell migration, survival, proliferation and 
angiogenesis. Abnormalities of PDGFR are involved in some diseases and cancers (Jones and 
Cross, 2004; Yu et al., 2003). For example, overexpression of PDGFRs may facilitate prostate 
cancer cell metastases to bone and overexpression of PDGFR α is associated with high 
mortality rate in ovarian cancer (Board and Jayson, 2005). Increased PDGF signaling via 
PDGFR β is observed in some vascular diseases, such as atherosclerosis and pulmonary 
hypertension (Dai, 2010). 
1.3 Signaling Pathways 
    When growth factors bind to RTKs, the receptors are phosphorylated and recruit many 
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intracellular signaling molecules. Several signaling pathways are then activated. The 
Ras-MAPK pathway and the PI3K-Akt pathway are the most important ones. 
1.3.1 The Ras-Mitogen Activated Protein Kinase Signaling Pathway 
Src homologous and collagen (Shc) adaptor family has 4 members: Shc (ShcA), ShcB (Sli) 
ShcC (Rai or N-Shc) and ShcD (RaLP) (Finetti et al., 2009). ShcA has 3 isoforms of 44, 52, 
and 66 kDa. p52 ShcA has been identified to couple RTKs to Ras-MAPK pathway to transfer 
activated tyrosine phosphorylation signaling. Unlike other isoforms, it is widely expressed in 
the cytoplasm and translocated to the plasma membrane after growth factor stimulation (Alam 
et al., 2009). p52 ShcA has an N-terminal PTB domain that can bind to the phosphotyrosine of 
RTK, a central proline-rich collagen homology (CH) 1 domain that includes 3 conserved 
tyrosine residues (Y239, Y240 and Y317) and a C-terminal SH2 domain that might also be 
responsible for binding to activated RTKs (Figure 1.6) (Cattaneo and Pelicci, 1998; 
Ravichandran, 2001; Zhang et al., 2003). These tyrosine residues in the CH1 domain can be 
phosphorylated by activated RTKs and become binding sites for other SH2 containing proteins. 
In addition, proteins including Src homology-3 (SH3) domain can target to proline-rich 
sequence in CH1 domain (Pellegrini et al., 2005). 
Growth factor receptor-bound protein 2 (Grb2) adaptor family has 3 members: Grb2, 
Grb2-related adapter protein (Grap) and Grb2-related adapter downstream of Shc (Gads) (Jang 
et al., 2009). Grb2 is a ubiquitously expressed cytoplasmic protein of 25 kDa and its central 
SH2 domain is flanked by 2 SH3 domains (Figure 1.6). It functions as a target for sequences 
containing either phosphotyrosine or abundant proline residues (Giubellino et al., 2008). Its 
SH2 domain can not only directly bind to activated RTK, but also interact with intracellular 
proteins containing specific phosphotyrosine, such as Y317-phosphorylated p52 ShcA 
(Cattaneo and Pelicci, 1998; Zhang et al., 2003). Its SH3 domains can bind to proline-rich 
proteins. For example, son of sevenless (Sos) 1 is constitutively linked to Grb2 (Giubellino et 
al., 2008). 
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Figure 1.6 The domain structures of several intracellular signaling proteins involved in 
the Ras-MAPK pathway. These proteins are p52 ShcA, Grb2, Sos1, Ras and Raf. The arrows 
show the interaction between domains of these proteins. 
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Sos has 2 identified human homologues and Sos1 (150 kDa) is a cytoplasmic Ras-specific 
guanine exchange factor (GEF) that activates Ras by converting GDP-bound Ras to GTP-bound 
Ras (Pierre et al., 2011; Watanabe et al., 2000). The N-terminal region of Sos has 2 tandem 
histone folds that can interact with the plasma membrane and control Sos1 function. The Dbl 
homology (DH) and pleckstrin homology (PH) domains are reported to negatively regulate Ras 
activation by blocking allosteric Ras binding site. Upon growth factor stimulation, Sos1 is 
recruited to the plasma membrane by forming Shc-Grb2-Sos complex and the autoinhibition is 
released to activate Sos. The Ras exchange motif (REM) and cell division cycle 25 (CDC25) 
domains can interact with GDP-bound Ras and provide the catalytic activity towards Ras to 
facilitate GDP for GTP exchange. The C-terminal region containing a specific P-X-X-P 
proline-rich sequence is responsible for binding to proteins containing SH3 domain, such as 
Grb2 (Figure 1.6) (Freedman et al., 2006; Pierre et al., 2011; Rojas et al., 2011; Sondermann et 
al., 2004). 
Ras, a 20-25 kDa small guanine-nucleotide-binding protein (G protein), is a member from 
the small GTPase superfamily and consists of H-Ras, K-RasA, K-RasB and N-Ras isoforms 
(Fehrenbacher et al., 2009; Rojas et al., 2012). It is localized to the plasma membrane by a lipid 
anchor after post-translational modification of the C-A-A-X sequence in the C-terminal 
hypervariable region (HVR) (Figure 1.6). The HVR linker domain may also contribute to the 
membrane localization. The N-terminal G domain is the guanine-nucleotide-binding site, which 
is the functional domain for GDP/GTP exchange (Abankwa et al., 2007; Eisenberg and Henis, 
2008; Fehrenbacher and Philips, 2009). Ras is a molecular switch cycled between 2 
conformations: active GTP-bound state and inactive GDP-bound state (Bivona and Philips, 
2003). GEFs, such as Sos1, bind to the GDP-bound state. Sos1 catalyzes bound GDP 
dissociation from the guanine nucleotide binding pocket of Ras and then GTP preferentially 
binds to the pocket because GTP is 10-fold more abundant than GDP in cytosol (Ahearn et al., 
2012). Thus, Ras is activated by GEFs due to the conformational change in the GTP-bound 
state. Its effector domain (G domain) can only trigger downstream signaling in the active 
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GTP-bound state (Avruch et al., 2001; Day et al., 1998; Fehrenbacher et al., 2009; Mor and 
Philips, 2006). GTPase activating proteins (GAPs) can deactivate Ras by activating the weak 
intrinsic GTPase activity of Ras to hydrolyze GTP to GDP, which can negatively regulate the 
Ras mediated signaling pathway (Bos et al., 2007; Vigil et al., 2010). 
Raf is a cytoplasmic serine/threonine protein kinase composed of 3 members: A-Raf, 
B-Raf, and C-Raf (Raf-1). B-Raf has high basal kinase activity compared to the other 2 
members (Maurer et al., 2011). Raf has 3 conserved regions (CRs) and multiple 
phosphorylation sites (Figure 1.6). The N-terminal CR1 is a regulatory domain that contains a 
Ras-binding domain (RBD) and a cysteine-rich domain (CRD) that interacts with the CR3 
kinase domain to inhibit kinase activity. 14-3-3 protein dimers bind to a specific phosphoserine 
site in the CR2 serine/threonine-rich domain to stabilize the inactive state and negatively 
control Raf activation (Leicht et al., 2007; Sridhar et al., 2005; Wellbrock et al., 2004). The 
effector domain of GTP-bound Ras binds to the RBD of Raf and relocalizes Raf to the plasma 
membrane. In addition, the specific serine residue in CR2 is dephosphorylated and 14-3-3 
proteins are dissociated upon Ras binding. Raf activation is through phosphorylation of 
multiple residues. There is another 14-3-3 binding site in the C-terminus of Raf, which is 
involved in positive regulation of the kinase activity (Beeram et al., 2005; Claperon and 
Therrien, 2007; Udell et al., 2011). In addition, it is suggested that Raf homodimerization or 
heterodimerization is also required for Raf activation (Matallanas et al., 2011; Roskoski, 2010). 
Once the GTP is hydrolyzed to GDP in Ras, Raf is released and becomes inactive (Leicht et al., 
2007). 
Mitogen activated protein kinase (MAPK) kinase/extracellular signal-regulated kinase 
(ERK) kinase (MEK) is a dual specificity kinase in cytoplasm that can phosphorylate threonine 
and tyrosine and is highly specific to MAPK (Shaul and Seger, 2007; Trujillo, 2011). There are 
2 isoforms: 45 kDa MEK1 and 46 kDa MEK2, which are about 80% identical and function 
equally in activation of MAPK (Shaul and Seger, 2007). Activated Raf can phosphorylate 2 
serine residues (Ser218 and Ser222 on MEK1, Ser222 and Ser226 on MEK2) in the 
18 
 
S-X-A-X-S/T motif in the activation loop of MEK and then activate MEK (Chapman and Miner, 
2011; Keshet and Seger, 2010; Shaul and Seger, 2007; Yoon and Seger, 2006). 
MAPK (ERK) is a cytoplasmic serine/threonine protein kinase with 2 isoforms: 42 kDa 
MAPK1 (ERK2) and 44 kDa MAPK3 (ERK1), that share about 70% similarity (Shaul and 
Seger, 2007). It can be phosphorylated on a threonine residue and a tyrosine residue (Thr183 
and Tyr185 in MAPK1, Thr202 and Tyr204 in MAPK3) located in the T-G-Y motif in the 
activation loop of MAPK and thus activated by MEK (Chang et al., 2003b; Keshet and Seger, 
2010; McCubrey et al., 2007; Rubinfeld and Seger, 2005). The substrates of MAPK include 
transcription factors (TFs), kinases, phosphatases, receptors and scaffold proteins. They have a 
consensus P-S/T-P or S/T-P sequence that can be phosphorylated because the kinase activity of 
MAPK is proline-directed. Activated MAPK can translocate into the nucleus and phosphorylate 
TFs. Activated TFs regulate gene expression involved in cell differentiation, proliferation, 
survival and migration. MAPK is also shown to participate in chromatin remodeling and 
nuclear import (Plotnikov et al., 2011; Rubinfeld and Seger, 2004; Yoon and Seger, 2006). 
Scaffold proteins, such as kinase suppressor of Ras (KSR), connector enhancer of KSR 
(CNK) and β-arrestin, play a critical role in the sequential activation of kinases (Dhanasekaran 
et al., 2007). They can form a multiprotein complex with 2 or more components (e.g. ERK, 
MAPK and sometimes Raf) and participate in the Ras-MAPK signaling pathway, which 
concentrates multiple kinases in an adjacent area, facilitates kinase activity and the sequential 
activation to accelerate signal transmission (Claperon and Therrien, 2007; Dard and Peter, 2006; 
Dhanasekaran et al., 2007; Udell et al., 2011; Yao and Seger, 2009; Yoon and Seger, 2006). 
In summary, the Ras-MAPK pathway is a cascade process that requires plenty of adaptor 
proteins and kinases (Figure 1.7). Initially, Shc is recruited to the phosphotyrosine residue of 
activated RTK via its PTB domain. RTKs phosphorylate tyrosine residues in Shc. Grb2 can 
bind to the phosphotyrosine residue in either RTK or Shc through its SH2 domain and 
translocate to plasma membrane. Grb2-associated Sos activates membrane-bound Ras by 
converting the GDP-bound state to the GTP bound state. Activated Ras results in sequential 
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Figure 1.7 Selected RTK-activated signaling pathways. When growth factors bind to RTKs, 
the receptors are phosphorylated and recruit many intracellular signaling molecules. Several 
signaling pathways are then activated. For the Ras-MAPK pathway, Shc is recruited to the 
phosphotyrosine residue of activated RTK, which phosphorylates tyrosine residues in Shc. 
Grab2 can bind to the phosphotyrosine residue in either RTK or Shc and translocate to the 
plasma membrane. Grb2-associated Sos activates membrane-bound Ras by converting the 
GDP-bound state to the GTP-bound state. GAP negatively regulates Ras. Activated Ras results 
in sequential activation of kinases (Raf, MEK and MAPK). The series of activated kinases are 
involved in regulation of gene expression that affects cellular functions. For the PI3K-Akt 
pathway, activation of PI3K by RTK catalyzes the phosphorylation of PI4,5P2 to PI3,4,5P3 and 
thereby recruits Akt to the plasma membrane. Akt is subsequently activated and phosphorylates 
a number of intracellular proteins involved in different cellular processes. PTEN reverses 
PI3K-induced lipid phosphorylation and switches off the PI3K-Akt pathway.  
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activation of kinases (Raf, MEK and MAPK). The series of activated kinases are involved in 
regulation of gene expression that affects many cellular functions. 
1.3.2 The Phosphatidylinositol 3 Kinase-Akt Signaling Pathway 
PI3K is a member of an intracellular lipid kinase family that phosphorylates the 3-position 
of the inositol ring of phosphatidylinositol and yields lipid second messengers. Based on the 
structure and function, it is divided into 3 classes: class I, class II and class III (Damilano et al., 
2010; Geering et al., 2007a; Ghigo et al., 2011). The best characterized class I PI3K 
preferentially takes part in converting phosphatidylinositol 4,5 bisphosphate (PI4,5P2) to 
phosphatidylinositol 3,4,5 trisphosphate (PI3,4,5P3). Depending on the receptor that activates 
class I PI3K, it is further divided into class IA PI3K that can be activated by RTKs and class IB 
PI3K that can be activated by GPCRs (Donato et al., 2010; Hawkins et al., 2006). Class IA 
PI3K is a heterodimer consisting of a regulatory subunit (p85α, p55α, p50α, p85β or p55γ) and 
a p110 catalytic subunit (p110α, p110β or p110δ) (Okkenhaug and Vanhaesebroeck, 2001; Ward 
et al., 2011). 
p85α is the best studied among 5 regulatory subunit isoforms of class IA PI3K. The 
N-terminal SH3 domain can bind to P-X-X-P sequences in proline-rich proteins (Figure 1.8). 
p85 monomers can form dimers via their own SH3 domain and the first proline-rich region. The 
following breakpoint cluster region homology (BH) domain can bind to GTPases (Fry and 
Waterfield, 1993) and has GAP activity (Chamberlain et al., 2004). The 2 proline-rich regions 
can interact with many proteins including its SH3 domain. In the C-terminus, a p110 binding 
domain is flanked by 2 SH2 domains that are responsible for binding to 
tyrosine-phosphorylated proteins containing pY-X-X-M motif such as activated RTKs. Both the 
nSH2 and p110 binding domain are involved in p110 binding (Backer, 2010; Geering et al., 
2007a; Krasilnikov, 2000; Wu et al., 2007). p85β shares the same domain structure as p85α. 
However, p55α, p50α and p55γ isoforms lack the N-terminal SH3 and BH domains and have 
different unique amino acid sequences in their N-terminus (Hawkins et al., 2006; Okkenhaug 
and Vanhaesebroeck, 2001). 
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Figure 1.8 The domain structures of several intracellular signaling proteins involved in 
the PI3K-Akt pathway. These proteins are class IA PI3K, Akt and PTEN. 
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The p110 catalytic subunit isoforms have similar structures. They all consist of a p85 
binding domain, a RBD domain, a protein kinase C homology 2 (C2) domain that has affinity 
for membrane, a helical domain (HD) involved in scaffold structure and a kinase domain 
(Figure 1.8) (Berndt et al., 2010; Zhao and Vogt, 2008). The N-terminal p85 binding domain 
interacts with the p110 binding domain in p85, which contributes to the dimerization between 
p85 and p110 and thus stabilizes and inhibits p110. Upon RTK activation, p85 docking to RTKs 
induces conformational change, relieves the inhibition of p110 by p85 and activates p110 
catalytic activity. As well, p85 binding to RTKs translocates PI3K to the plasma membrane to 
facilitate the approach to PI4,5P2 by p110 (Backer, 2010; Fu et al., 2004; Geering et al., 2007b; 
Vadas et al., 2011; Yu et al., 1998). The RBD domain binding to GTP-bound Ras can also 
promote p110 kinase activity, which links PI3K activation with the Ras-MAPK pathway 
(Hawkins et al., 2006). The activated PI3K catalyzes the phosphorylation of PI4,5P2 to 
PI3,4,5P3, which provides binding sites for proteins containing PH domain, such as Akt and 
phosphoinositide-dependent kinase (PDK) (Donato et al., 2010; Song et al., 2005; Vadas et al., 
2011). 
Akt, also called protein kinase B (PKB), is a 57 kDa serine/threonine kinase consisting of 
3 isoforms: Akt1, Akt2 and Akt3. They all share the same structure with the kinase domain 
flanked by a PH domain and a regulatory domain (Figure 1.8). Akt binding to PI3,4,5P3 through 
its N-terminal PH domain localizes Akt to the plasma membrane and causes a conformational 
change to expose phosphorylation residues (Fresno Vara et al., 2004; Osaki et al., 2004; Scheid 
and Woodgett, 2003; West et al., 2002). Akt can be phosphorylated at a threonine residue 
(Thr308 in Akt1, Thr309 in Akt2, Thr305 in Akt3) in the activation loop by PDK1 and a serine 
residue (Ser473 in Akt1, Ser474 in Akt2, Ser472 in Akt3) in the C-terminus to become fully 
activated (Chang et al., 2003a; Nicholson and Anderson, 2002; Osaki et al., 2004; Song et al., 
2005). The kinase that phosphorylates the serine residue was unclear for a long time and recent 
research shows that mammalian target of rapamycin complex 2 (mTORC2) is the predominant 
kinase responsible for the serine residue phosphorylation (Hay, 2011; Hers et al., 2011). 
23 
 
Activated Akt can translocate into the cytoplasm or the nucleus and phosphorylate various 
substrates containing R-X-R-X-X-S/T-ψ sequences (ψ is a bulky hydrophobic residue), such as 
the Bcl-2/Bcl-X antagonist of cell death (BAD), caspase-9 and glycogen synthase kinase (GSK) 
3 (Hanada et al., 2004; Hers et al., 2011). Akt1 is widely distributed and can regulate cellular 
processes including protein synthesis, cell cycle control, apoptosis, proliferation and survival 
(Chang et al., 2003a; Kandel and Hay, 1999). Akt2 plays a role in insulin signaling, while Akt3 
functions in brain development (Almhanna et al., 2011; Chaanine and Hajjar, 2011). 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a 47 kDa dual 
lipid/protein phosphatase that mainly functions in dephosphorylation of PI3,4,5P3 to PI4,5P2 
(Blanco-Aparicio et al., 2007; Knobbe et al., 2002). It functions as a tumor suppressor by 
antagonizing PI3K and negatively regulating PI3K-Akt pathway (Simpson and Parsons, 2001; 
Yin and Shen, 2008). Its PI4,5P2 binding domain (PBD), phosphatase domain and C2 domain 
are responsible for lipid binding and both phosphatase and C2 domains confer the catalytic 
activity (Figure 1.8). There are multiple threonine and serine residues for phosphorylation and a 
PSD-95/Dlg/ZO-1 binding (PDZB) motif (Leslie and Downes, 2004; Steelman et al., 2004; 
Tamguney and Stokoe, 2007). These phosphorylated residues can interact with the phosphatase 
and C2 domains to stabilize PTEN and block membrane localization, playing a regulatory role. 
Dephosphorylation of these residues releases the C-terminal tail from these functional domains 
and allows plasma membrane localization via newly exposed basic residues in the phosphatase 
and C2 domains, as well as the PBD (Maehama et al., 2004). The PDZB motif binds 
PDZ-containing scaffold proteins such as Na
+
/H
+
 exchanger regulatory factor (NHERF) and 
membrane-associated guanylate kinase with inverted organization (MAGI) proteins that further 
localize PTEN to sites of RTK-associated PI3K lipid products (Bonifant et al., 2007; Mellor et 
al., 2012). PTEN is also a weak phosphatase towards some proteins including itself though the 
significance of these protein targets is unclear (Knobbe et al., 2002; Tamguney and Stokoe, 
2007). 
In summary, the PI3K-Akt pathway starts by the p85 regulatory subunit binding to 
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activated RTKs via SH2 domains. This activates the p110 catalytic subunit and localizes PI3K 
to the plasma membrane. Then PI3K catalyzes the phosphorylation of PI4,5P2 to PI3,4,5P3 and 
thereby recruits Akt to the plasma membrane. Akt is subsequently activated and phosphorylates 
a number of intracellular proteins involved in different cellular processes. PTEN reverses 
PI3K-induced lipid phosphorylation and switches off the PI3K-Akt pathway (Figure 1.7). 
1.4 Receptor-Mediated Endocytosis 
Endocytosis is a cellular process in which a variety of molecules are taken up from the cell 
surface into cells (Scita and Di Fiore, 2010). There are different methods to perform the 
internalization, such as phagocytosis, pinocytosis, clathrin-dependent endocytosis and 
clathrin-independent endocytosis (Sahay et al., 2010; Zaki and Tirelli, 2010). They are involved 
in several processes including extracellular nutrients uptake, synaptic vesicle recycling, cell 
surface receptor expression regulation, plasma membrane remodeling and cell polarity 
maintenance (Mukherjee et al., 1997). After internalization, the majority of molecules are 
recycled back to the cell surface or degraded in lysosomes. However, some molecules may 
traffic to organelles such as Golgi and endoplasmic reticulum (Sigismund et al., 2012). 
Receptor-mediated endocytosis of RTK plays an important role in normal physiological 
functions since continuously activated RTKs and signaling pathways are usually correlated with 
cancers and other diseases. Receptor-mediated endocytosis is ligand induced and regulates 
signaling pathways by limiting the numbers of RTKs for activation (Sorkin and von Zastrow, 
2009). It removes activated RTKs from the plasma membrane and regulates RTKs accessibility 
to the plasma membrane and their ligands. It also disassociates ligands from RTKs and 
dephosphorylates RTKs to downregulate signal transduction. Some RTKs are even degraded in 
lysosomes (McMahon and Boucrot, 2011; Sigismund et al., 2012; Sorkin and Von Zastrow, 
2002). 
Clathrin-mediated receptor endocytosis is the best studied and most widely used 
mechanism for RTK internalization (Takei and Haucke, 2001). It occurs at specific sites with 
25 
 
clathrin-coated pits. Clathrin has 3 heavy chains and 3 light chains that are organized in a 
triskelion structure. Clathrin forms lattice-like clathrin-coated pit around the inner membrane, 
which is mediated by adaptor proteins (e.g. AP-2). AP-2 has a phospholipid-binding motif that 
preferentially binds to PI4,5P2 on the plasma membrane (Mousavi et al., 2004; Sorkin, 2004; 
Zaki and Tirelli, 2010). It also facilitates activated RTKs clustering with clathrin. Clathrin does 
not bind to RTKs or the plasma membrane directly. The clathrin polymerization by AP-2 
triggers invagination and budding of clathrin-coated pits (Boettner et al., 2012; Scita and Di 
Fiore, 2010; Sigismund et al., 2012). The mature vesicles are eventually cleaved from cell 
membrane by dynamin at the neck. Dynamin is a GTPase with a PH domain that can bind to 
PI4,5P2. The polymerization of dynamin and GTP hydrolysis promote the vesicle scission. 
Once the vesicles are free in cytoplasm, the clathrin coat is disassembled from the vesicles and 
the components are recycled. The uncoated vesicles are able to tether to and fuse with 
early/sorting endosomes, which is mediated by the Rab5 GTPase (McMahon and Boucrot, 2011; 
Takei and Haucke, 2001; Ungewickell and Hinrichsen, 2007). 
Caveolae-mediated receptor endocytosis is the most common clathrin-independent 
mechanism. Caveolin is a small flask-shaped scaffold protein that can oligomerize to form lipid 
rafts with the invaginating part of the plasma membrane (Nabi and Le, 2003; Parton and 
Richards, 2003). Like clathrin-mediated endocytosis, the scission of budding vesicles from the 
plasma membrane is also dynamin dependent and followed by vesicle uncoating, tethering and 
fusion (Doherty and McMahon, 2009; Sandvig et al., 2011; Sverdlov et al., 2007). 
Rab proteins are a family of monomeric small Ras-related GTPases that cycle between 
active GTP-bound forms and inactive GDP-bound forms. There are more than 60 Rabs that 
have been identified and many of them are widely expressed (Pfeffer, 2001; Seabra et al., 2002). 
They participate in intracellular vesicle transport and determine the specificity during vesicle 
fusion and sorting in endocytosis by recruiting certain effectors to specific membranes 
(Hammer and Wu, 2002; Jordens et al., 2005; Stenmark, 2009). The post-translational 
isoprenylation modification of Rabs in the C-terminus allows for membrane binding 
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(Pereira-Leal et al., 2001). GDP-bound Rabs are usually present in cytoplasm and associate 
with guanine-nucleotide-dissociation inhibitors (GDIs) to bind the isoprenyl group to remove 
the Rab from a membrane. GDIs inhibit GDP release and stabilize the inactive form. When 
GDI-displacement factors (GDFs) target to Rab-GDP-GDI complexes, GDIs are released. This 
causes conformational change and exposes the prenyl group and allows Rab membrane 
localization to a specific vesicle. GEFs and GAPs respectively regulate the activation and 
deactivation processes of Rabs, much as they do for Ras proteins. Active GTP-bound Rabs 
recruit the specific effectors for membrane trafficking. GDIs can bind to and extract the inactive 
GDP-bound Rabs from the membrane (Goody et al., 2005; Horgan and McCaffrey, 2011; 
Seabra and Wasmeier, 2004). 
The internalized vesicles containing RTKs fuse with the early/sorting endosomes in a 
Rab5-mediated process. Early endosome antigen 1 (EEA1) can bind to active Rab5 and 
phosphatidylinositol 3-phosphate (PI3P) on different endosomes, and thus tether the 2 endosomes 
together. The soluble N-ethylmaleimide sensitive factor attachment receptor (SNARE) complex 
formed by EEA1 tethering promotes the fusion event. As well, Rab5 can bind to phosphatases that 
can yield PI3P from PI3,4,5P3 (Neel et al., 2005; Pfeffer, 2001; Stenmark, 2009; Teis and Huber, 
2003). 
When receptors are transported to the early/sorting endosomes, ligands are detached and 
receptors are dephosphorylated and deactivated. There are 3 possible pathways for sorting RTKs 
from early/sorting endosomes (Figure 1.9) (Scita and Di Fiore, 2010; Sorkin and Goh, 2008). The 
detailed mechanism is not fully understood yet. Some receptors are rapidly recycled back to the 
plasma membrane, which is regulated by Rab4. Some receptors are slowly recycled back to the 
plasma membrane via intermediate recycling endosomes, which is regulated by Rab4 and Rab11 
(Neel et al., 2005; Platta and Stenmark, 2011; Sadowski et al., 2009). Some receptors are sorted to 
be degraded via the late endosomes and lysosomes, which is regulated by Rab7. Only a small 
fraction of receptors which are monoubiquitinated may be diverted into multivesicular bodies 
(MVBs) by endosomal sorting complexes required for transport (ESCRTs) that are linked to the 
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Figure 1.9 Receptor-mediated endocytosis. Activated RTKs are rapidly endocytosed via 
clathrin-dependent or clathrin-independent manner and transported to the early endosomes for 
sorting. Some receptors are dephosphorylated and rapidly recycled back to the plasma 
membrane. Some receptors are dephosphorylated and slowly recycled back to the plasma 
membrane via the intermediate recycling endosomes. Some receptors are sorted to be degraded 
via the late endosomes and lysosomes. Rab GTPases regulate vesicle fusion and sorting.  
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endosomal membrane. Mature MVBs within the late endosomes are then delivered to the 
lysosomes for degradation. The ubiquitination of receptors is induced by E3 ubiquitin ligases in 
the early steps of endocytosis (Jordens et al., 2005; Seabra et al., 2002; Sorkin and von Zastrow, 
2009; Teis and Huber, 2003). 
1.5 Ankyrins 
Ankyrin is a family of intracellular adaptor proteins that associates with integral 
membrane proteins and cytoskeleton proteins and acts as a linker between plasma membrane 
proteins and the cytoskeleton. It can translocate and anchor membrane proteins, thus stabilizing 
them by providing structural support (Mohler, 2006; Rubtsov and Lopina, 2000). It has 3 
members: ankyrin1 (ankyrin R, R for restricted expression), ankyrin2 (ankyrin B, B for broad 
expression) and ankyrin3 (ankyrin G, G for general expression). Ankyrin1 is found in 
erythrocyte, brain, cardiac muscle and skeletal muscle, and mainly in erythrocyte. Ankyrin2 is 
expressed in brain, heart and thymus. Ankyrin3 is expressed in brain, heart, kidney, lung, liver, 
intestine, skeletal muscle and epidermis. However, ankyrin2 and ankyrin3 are primarily 
expressed in heart (Cunha and Mohler, 2006; Curran and Mohler, 2011). These members all 
have several isoforms based on the alternative splicing of genes encoding for ankyrin (Hashemi 
et al., 2009).  
Ankyrin1, ankyrin2 and ankyrin3 share the same domain structure that consists of an 
N-terminal membrane protein-binding domain, a spectrin-binding domain, a death domain and 
a C-terminal regulatory domain (Figure 1.10) (Bennett and Healy, 2008; Rubtsov and Lopina, 
2000). The membrane protein-binding domain has 24 ankyrin repeats that each consists of 33 
amino acids and 2 α-helices linked by β-hairpin loop. These ankyrin repeats are organized in a 
superhelical spiral structure and mediate interactions with membrane proteins in a multivalent 
manner (Cunha and Mohler, 2011; Czogalla and Sikorski, 2010; Ignatiuk et al., 2006; Mohler, 
2006). The spectrin-binding domain can bind to β-spectrin in the cytoskeleton and thus links 
membrane proteins to the cytoskeleton (Hashemi et al., 2009). The role of death domain is still 
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Figure 1.10 The domain structure of ankyrin. Ankyrin consists of an N-terminal membrane 
protein-binding domain, a spectrin-binding domain, a death domain and a C-terminal regulatory 
domain. The smaller isoforms of ankyrin3 (ankyrin120 and ankyrin105) lack the membrane 
protein-binding domain, but have 6 unique amino acids in the N-terminus. Ankyrin120 has an 
insert in its regulatory domain.  
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unclear, but it has been shown that death domain of ankyrin3 in renal tubules is related to cell 
death. It is the most highly conserved in sequence and may function together with regulatory 
domain (Bennett and Healy, 2009; Mohler, 2006). The regulatory domain is the most divergent 
among all 3 members. It controls the affinity of ankyrin binding to specific membrane proteins 
and spectrin (Cunha and Mohler, 2006; Lambert and Bennett, 1993). 
Ankyrin3 is the most recently characterized and the most widely distributed. It is 
expressed in different isoforms of 480 kDa, 270 kDa, 215 kDa, 200 kDa, 190 kDa, 170 kDa and 
100-120 kDa depending on cell type (De Matteis and Morrow, 1998; Ignatiuk et al., 2006; 
Rubtsov and Lopina, 2000). Some isoforms have inserts between the membrane protein-binding 
domain and the spectrin-binding domain and/or within the regulatory domain. The larger 
isoforms containing all domains are plasma membrane-associated proteins. The smaller 
isoforms (e.g. ankyrin120 and ankyrin105) lack the N-terminal membrane protein-binding 
domain and are localized to late endosomes and lysosomes (Figure 1.10) (Ignatiuk et al., 2006). 
They have 6 unique amino acids in the N-terminus. In addition, ankyrin120 has an insert in its 
regulatory domain (Hoock et al., 1997; Peters et al., 1995). Our laboratory has previously used 
a phage display library to select hexapeptides that could bind to the SH2 domain of the PI3K 
regulatory subunit p85 (King et al., 2000). Ankyrin3 was considered as a possible p85-binding 
protein due to the presence of the hexapeptides that can bind to p85 SH2 domain. Subsequently, 
our laboratory has shown that p85 directly binds to the smaller isoforms (ankyrin120 and 
ankyrin105) of ankyrin3 and the binding requires the spectrin-binding domain and the 
regulatory domain of ankyrin3, and p110-binding domain and cSH2 domain of p85 (Ignatiuk et 
al., 2006). Overexpression of ankyrin120 and ankyrin105 promotes lysosomal-mediated 
degradation of the PDGFR in NIH 3T3 cells and differentially affects PDGFR downstream 
signaling pathways (Ignatiuk et al., 2006). These results suggest that the smaller isoforms of 
ankyrin3 might facilitate RTK degradation and downstream signaling pathway downregulation. 
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1.6 Cancer Therapeutics to Downregulate ErbB2 
Breast cancer is the most common cancer in women and the second leading cancer that 
causes death (Howard and Bland, 2012). Statistics suggests that about 200,000 cases of breast 
cancer occur every year in the United States, which is about 30% of the annual new cancer 
cases (Dean-Colomb and Esteva, 2008; Engel and Kaklamani, 2007). It is predicted that the 
morbidity in women in their lifetime risk is 1 in 8 (Downs-Holmes and Silverman, 2011). 
Breast cancer is identified as a heterogeneous disease including 5 major subtypes by studying 
the gene expression profiling using DNA microarrays (Van der Auwera et al., 2010). The 
classification of subtypes is based on estrogen receptor (ER), progesterone receptor (PR) and 
ErbB2 status (Nguyen et al., 2008). According to ER expression, there are 2 categories: 
ER-positive tumors (luminal A and luminal B subtypes) and ER-negative tumors 
(ErbB2-positive, basal-like and normal-like subtypes) (Bertucci et al., 2012; Geyer et al., 2012). 
Luminal A (ER+ or PR+ and ErbB2-) and luminal B (ER+ or PR+ and ErbB2+) subtypes have 
similar expression profiles in luminal mammary epithelial cells. But they have different 
expression of ER-related genes and proliferative genes, giving rise to different survival rates 
(Bertucci et al., 2012; Nguyen et al., 2008). ER-negative tumors have relatively low expression 
of ER and PR and are usually associated with poor prognosis, high recurrence rate and low 
survival rate compared to ER-positive tumors (Toft and Cryns, 2011). ErbB2-positive (ER- or 
PR- and ErbB2+) subtype is more aggressive and worse prognosis than ErbB2-negative 
subtypes (Mukai, 2010). It is shown that about 20% to 30% of breast cancer results from ErbB2 
overexpression (Pedersen et al., 2008). Basal-like and normal-like tumors substantially overlap 
with triple-negative (ER-, PR- and ErbB2-) breast cancer (Carey et al., 2010; Pal et al., 2011). 
Basal-like tumors take up 15% to 25% of breast cancer cases (Rakha and Ellis, 2009). The 
study of different subtypes may help to improve the understanding of clinical characteristics of 
breast cancer and develop new strategies for prognosis and therapeutic treatment (Espinosa et 
al., 2011; Finnegan and Carey, 2007). 
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ErbB2 has a constitutively exposed dimerization arm, which can homodimerize and 
heterodimerize with other members of the EGFR subfamily without ligand docking (Burgess et 
al., 2003). ErbB2 is internalization resistant, so ErbB2-containing dimers may have enhanced 
and prolonged activation of receptors and downstream signaling pathways (Hommelgaard et al., 
2004). Overexpression of ErbB2 is usually linked to cancers, especially breast cancer (Pedersen 
et al., 2008). Therefore, ErbB2 has been characterized as a viable target for cancer therapeutics. 
Many drugs that can directly target to ErbB2 or induce ErbB2 downregulation have been 
developed due to the increasing understanding of ErbB2 (Higgins and Baselga, 2011; Sachdev 
and Jahanzeb, 2012).  
1.6.1 Geldanamycin 
    Geldanamycin (GA) and its analog 17-allylamino-17-demethoxygeldanamycin (17-AAG) 
are benzoquinone ansamycin antibiotics that can inhibit heat shock protein (Hsp) 90 chaperone 
function (Austin et al., 2004; Neckers et al., 1999). Hsp90 is widely expressed, but at high 
levels in cancer cells. It can bind to multiple client proteins including ErbB2, p53 and Akt, and 
stabilize them. Hsp90 has an N-terminal ATPase domain that has a conserved 
ATP/ADP-binding pocket. Hsp90 cycles between 2 conformations based on ATP or ADP 
binding (Chiosis et al., 2004; Hao et al., 2010). In the ADP-bound form, client proteins bind to 
Hsp90, which is mediated by the Hsp40/Hsp70 complex and the Hsp40/Hsp70 organizing 
protein (HOP). In the ATP-bound form, Hsp40/Hsp70 and HOP are released and the mature 
complex with client protein is formed (Fukuyo et al., 2010). Geldanamycin competitively binds 
to the ATP/ADP-binding pocket and then Hsp90 mimics the ADP-bound form. The associated 
Hsp70 recruits the E3 ligase heat shock cognate protein 70-interacting protein (HIP) and the 
client protein is ubiquitinated and sorted for degradation via the proteasome (Blagosklonny, 
2002; Neckers, 2002; Pedersen et al., 2009). It has been demonstrated that geldanamycin 
promotes ErbB2 downregulation from the plasma membrane, but the mechanism and whether it 
is via a clathrin-dependent or proteasome-dependent manner is still controversial (Barr et al., 
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2008; Lerdrup et al., 2006; Pedersen et al., 2008). Although its anti-cancer potential has been 
confirmed in vitro, geldanamycin is still not used in clinical treatment because it has severe 
hepatotoxicity in animal models when using a therapeutically effective dose (Supko et al., 
1995). In addition, it is not soluble in water and not metabolically stable, which suggests that it 
is not a good candidate for drug development. Different geldanamycin derivatives have been 
developed to minimize these limitations (Fukuyo et al., 2010; Le Brazidec et al., 2004). 
1.6.2 Herceptin 
    Nowadays, a variety of molecules that can specifically bind to the extracellular or 
intracellular domain of ErbB2 have been identified as drugs for cancer therapy. Monoclonal 
antibodies or ligand antagonists have been used to bind to the extracellular domain, whereas the 
binding to the intracellular domain is performed by tyrosine kinase inhibitors (TKIs) (Saxena 
and Dwivedi, 2012). 
Herceptin (Trastuzumab) is a humanized monoclonal antibody against ErbB2 extracellular 
domain IV. It is the first drug that can target to ErbB2 that was approved by the FDA and has 
been used in clinical treatment for ErbB2-positive cancer for more than 10 years (Pegram and 
Liao, 2012). It has 2 antigen-specific binding sites. The targeting of herceptin to extracellular 
domain of ErbB2 blocks ErbB2-induced dimerization and inhibits intracellular tyrosine kinase 
activity (Hudis, 2007). It can facilitate ErbB2 internalization and degradation, interrupt 
intracellular downstream signaling pathways and prevent tumorigenesis (Sachdev and Jahanzeb, 
2012; Spector and Blackwell, 2009). However, herceptin has some side effects such as cardiac 
toxicity, neutropenia and anemia (Chen et al., 2011; Chien and Rugo, 2010). In addition, some 
patients have inherent or acquired resistance to herceptin that may lead to relapse. The 
resistance results from other molecules that can interact with ErbB2 (Arteaga et al., 2012). For 
example, blockage of ErbB2 may contribute to an increase in the expression of other EGFR 
members as a compensating response (Arpino et al., 2007). PTEN loss, PI3K mutation and 
abnormality of the extracellular domain of ErbB2 are the mechanisms that have been shown to 
contribute to herceptin resistance (Dean-Colomb and Esteva, 2008; Mukai, 2010). 
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2.0 RATIONAL AND OBJECTIVES 
     Our laboratory has previously shown that the PI3K regulatory subunit p85 directly binds 
to the smaller isoforms (ankyrin120 and ankyrin105) of ankyrin3. Overexpression of 
ankyrin120 and ankyrin105 promotes lysosomal-mediated degradation of the PDGFR in NIH 
3T3 cells and differentially affects PDGFR downstream signaling pathways (Ignatiuk et al., 
2006). These results suggest that the smaller isoforms of ankyrin3 might facilitate RTK 
degradation and downstream signaling pathway downregulation. To determine whether 
ankyrin105 can induce degradation of multiple RTKs similarly, we extended these studies to 
EGFR and its downstream signaling in this project. 
2.1 Hypothesis 
Ankyrin105 facilitates degradation of EGFR and enhances the downregulation of signaling 
pathways. 
2.2 Specific Objectives 
1. Determine effect of ankyrin105 expression on EGFR levels and activation state. 
2. Characterize downstream EGFR signaling in selected ankyrin105 expression cells. 
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3.0 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Cell Lines and Tissue Culture Conditions 
Five cell lines were selected for this thesis, which were COS-1, HEK293T, MCF10A, 
MDA-MB-231 and AU565, respectively. All cell lines were purchased from American Type 
Culture Collection (ATCC), except for HEK293T cell, which was received from Dr. Roesler’ s 
laboratory (Department of Biochemistry, University of Saskatchewan). Detailed information 
and features of each cell line are shown in Table 3.1. EGFR and ErbB2 levels of three breast 
cell lines are shown in Table 3.2. Cell culture media and condition are shown in Table 3.3. 
MCF10A cells were detached from the plates by TrypLE Express (Gibco 12605) and cells from 
all other cell lines were trypsinized by Trypsin-EDTA (ethylene diamine tetraacetic acid) 
(Gibco 15400).  
Special safety precautions were used when working with cholera toxin. Biosafety Level 2 
rules in the Biosafety Manual and Hazardous Waste Disposal Manual (from Department of 
Health, Safety and Environment, University of Saskatchewan) were followed. Biohazard signs 
were placed on the biological safety cabinet (BSC) and incubator. All the experiments that 
required cholera toxin were done in BSC. Two pairs of gloves and a disposable lab coat were 
worn and disposable plasticware were used when handling cholera toxin. Before the experiment, 
bench coat was placed on the working area in BSC. After the experiment, waste solution was 
inactivated with 10% bleach for 1 hour prior to disposal. All other waste, including plates, tubes, 
plastic pipettes, plastic pipettes, gloves, etc., were decontaminated with 10% bleach for 1 hour, 
and then sealed in labeled double bags and sent for disposal. The BSC working area was also 
decontaminated with 10% bleach for 1 hour and then wiped down with distilled water and 70% 
ethanol. 
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Table 3.1 Selected cell lines and features 
Cell Line 
Catalogue 
Number 
Cell Type Feature 
COS-1 CRL-1650 
Simian Vacuolating Virus 40 (SV40) 
transformed African green monkey 
kidney fibroblast-like cell 
express EGFR 
HEK293T N/A 
SV40 transformed human embryonic 
kidney cell 
express EGFR 
MCF10A CRL-10317 
immortalized human breast epithelial 
cell, not tumorigenic or transformed 
express EGFR 
MDA-MB-231 HTB-26 human breast cancer epithelial cell express EGFR 
AU565 CRL-2351 human breast cancer epithelial cell 
express EGFR 
and ErbB2 
 
 
Table 3.2 Semiquantitative measurement of EGFR and ErbB2 levels in three human 
breast cell lines. EGFR and ErbB2 levels were measured and normalized from Western blots 
using Scion Image software. The data were taken from a protein file (Neve et al., 2006). 
 MCF10A MDA-MB-231 AU565 
EGFR 821 5994 6085 
ErbB2 705 1991 10750 
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Table 3.3 Culture media and growth conditions of cell lines used 
Cell Line Cell Culture Media 
Cell Culture 
Conditions 
COS-1 
Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco 12100), 10% fetal bovine serum (FBS, PAA 
A15-237) 
37ºC, 5% CO2 
HEK293T 
Dulbecco’s Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F-12, Gibco 12500), 10% 
FBS 
37ºC, 5% CO2 
MCF10A 
advanced DMEM/F-12 (Gibco 12634), 5% horse 
serum (PAA B15-023), 10 μg/mL insulin (Sigma 
I1882), 10 ng/mL EGF (Sigma E9644), 0.5 μg/mL 
hydrocortisone (Sigma H0888), 1 mM L-glutamine 
(Sigma G2150), 0.1 μg/mL cholera toxin (Sigma 
C8052) 
37ºC, 5% CO2 
MDA-MB-231 Leibovitz’s L-15 Medium (Gibco 41300), 10% FBS 37ºC, 100% air 
AU565 
Roswell Park Memorial Institute (RPMI) Medium 
1640 (Gibco 31800), 10% FBS, 10mM HEPES 
(Sigma H3375), 1 mM sodium pyruvate (Gibco 
890-1840IM), 2.5 mg/mL D-glucose (BDH 
B10117) 
37ºC, 5% CO2 
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3.1.2 Plasmids and Adenovirus Vectors 
pHA3 plasmid encoding 3 copies of hemagglutinin (HA) (YPYDVPDYA) was constructed 
by Yun Fang, which was modified from pRc/CMV2 vector (Invitrogen) (Figure 3.1) (King et 
al., 2000). The vector has an SV40 replication origin, which would help the vector replicate in 
SV40 transformed cells, such as COS-1 and HEK293T cells (Ali and DeCaprio, 2001; Asano et 
al., 1985). The cytomegalovirus (CMV) promoter produces high expression of insert gene in a 
variety of mammalian cells. pHA3 plasmid is used as a control for other recombinant plasmids 
modified from itself, which would be pHA3-Ank105 in this thesis. 
Recombinant pHA3-Ank105 plasmid was generated by Josh Giroux. Ankyrin105 (amino 
acids 874-1588, 1783-1961) has spectrin-binding domain and regulatory domain but without 
insert A, B and C. Ankyrin105 DNA and pHA3 vector were both digested by BglII and EcoRI. 
Then ankyrin105 DNA was subcloned into the vector. There were 6 unique amino acids 
(MALPHS) in the N-terminal region of ankyrin105, which would be expressed right after the 
HA tags in the resulting fusion protein HA-Ank105 (Ignatiuk et al., 2006). 
pEGFP-C1 plasmid (BD Biosciences 6084-1) contains SV40 replication origin and CMV 
promoter, which would help to get high expression of inserted green fluorescent protein (GFP) 
gene (Figure 3.2). This plasmid was used to optimize the amount of plasmid DNA for calcium 
phosphate transfection in this thesis. 
There were 2 adenoviral vectors used in the experiments. Adenovirus-CMV-GFP control 
(Ad-GFP) (Vector Biolabs 1060) was constructed using adenovirus-type 5 (dE1/E3) and 
expressed GFP. It had a titer of 1×10
10
 plaque forming units (PFU)/mL and was stored at -80ºC. 
It was commonly used as a control for other recombinant adenoviruses using the Ad-GFP viral 
backbone, which would be adenovirus-CMV-GFP+HA3-Ank105 (Ad-GFP+HA-Ank105) in 
this thesis. The HA-Ank105 gene was cloned into a shuttle vector by Levi Furber. Then the 
vector was sent to Vector Biolabs for custom adenovirus construction service. The recombinant 
adenovirus Ad-GFP+HA-Ank105 used the Ad-GFP viral backbone and expressed both GFP 
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Figure 3.1 Map of pRc/CMV2 plasmid and modifications to generate pHA3. The figure was 
modified from Invitrogen website (http://tools.invitrogen.com/content/sfs/manuals/prccmv 
2_man.pdf). This plasmid contains CMV promoter, T7 promoter, bovine growth hormone 
(BGH) polyadenylation signal, f1 origin, SV40 replication origin, neomycin resistance gene, 
SV40 polyadenylation signal, ColE1 origin, ampicillin resistance gene and multiple restriction 
sites for gene insertion. Three copies of HA were cloned into these multiple restriction sites.  
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Figure 3.2 Map of pEGFP-C1 plasmid. The figure was taken from Molecular Info website 
(http://www.molecularinfo.com/MTM/K/K2/K2-1/pEGFPc1.pdf). This plasmid contains CMV 
promoter, GFP gene, SV40 polyadenylation signal, f1 origin, SV40 replication origin, SV40 
promoter, kanamycin/neomycin resistance gene, herpes simplex virus (HSV) thymidine kinase 
(TK) polyadenylation signal, pUC replication origin and multiple restriction sites for gene 
insertion. 
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and HA-Ank105. GFP and HA-Ank105 genes were from the same transcript, but expressed as 
2 separate proteins. Ad-GFP+HA-Ank105 had the titers of 6.2×10
10
 PFU/mL and 5.6×10
10
 
PFU/mL (from different batches) and was stored at -80ºC. 
3.1.3 Antibodies 
Different antibodies were used in the experiments for either Western blot (WB) or flow 
cytometry (FCM). Detailed information and working conditions for these antibodies are listed 
in Table 3.4. 
3.1.4 Other Reagents and Supplies 
All chemicals and reagents used in the experiments were analytical grade or higher and 
were purchase from VWR, Sigma or BDH, unless otherwise indicated. The compositions of the 
buffers are listed in Table 3.5. 
3.2 Cell Culture Techniques 
3.2.1 Transient Transfection 
3.2.1.1 COS-1 Cells Transfection 
    HA-Ank105 was introduced into COS-1 cells by transient transfection using 
Lipofectamine reagent (Invitrogen 18324). COS-1 cells were split 1:5 into 10 cm plates on day 
1, which were then about 40% confluent by the next day. On day 2, 3 μg or 6 μg plasmid DNA 
encoding HA-Ank105 was added into 600 μL Opti-MEM Reduced Serum Media (Gibco 31985) 
and then combined with a mixture of 600 μL Opti-MEM Reduced Serum Media and 18 μL 
Lipofectamine reagent. After 15 minutes incubation at room temperature, 4.8 mL serum-free 
DMEM was added to the combined solution to make the transfection media. For each 10 cm 
plate, the cells were washed once with 5 mL warm serum-free DMEM and the 6 mL 
transfection media was added to the cells. The cells were incubated at 37ºC and 5% CO2 for 5 
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Table 3.4 List of antibodies 
Antibody 
Company and 
Catalogue Number 
Species Working Condition 
Ankyrin 3 (AP) Dr. Anderson lab made rabbit WB: 1 μg/mL 
EGFR (C74B9) Cell Signaling, 2640 rabbit WB: 1:1000 
HER2/ErbB2 (29D8) Cell Signaling, 2165 rabbit WB: 1:1000 
Phospho-Tyr (PY20) Santa Cruz, sc-508 mouse WB: 2 μg/mL 
Akt Cell Signaling, 9272 rabbit WB: 1:1000 
Phospho-Akt (Ser473) 
(pAkt) 
Cell Signaling, 9271 rabbit WB: 1:1000 
ERK1 (MAPK) BD, 610030 mouse WB: 1:1000 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
(pMAPK) 
Cell Signaling, 9101 rabbit WB: 1:1000 
GFP (FL) Santa Cruz, sc-8334 rabbit WB: 1 μg/mL 
HA-probe (F7) Santa Cruz, sc-7392 mouse WB: 1 μg/mL 
GAPDH Ambion, AM4300 mouse WB: 1 μg/mL 
IRDye 680 Goat 
anti-Rabbit IgG  
LI-COR, 926-32221 goat WB: 1:10000 
IRDye 680 Goat 
anti-Mouse IgG 
LI-COR, 926-32220 goat WB: 1:10000 
IRDye 800CW Goat 
anti-Mouse IgG  
LI-COR, 926-32210 goat WB: 1:10000 
Neu (9G6) Santa Cruz, sc-08 mouse FCM: 0.5 μg/1×106 cells 
Goat anti-Mouse IgG1-PE Santa Cruz, sc-3764 goat FCM: 0.5 μg/1×10
6 
cells 
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Table 3.5 Buffer compositions 
Buffer Composition 
Blocking buffer 
(for most Western blots) 
5% (w/v) Carnation skim milk powder in PBS 
Blocking buffer 
(for pTyr blots) 
1% (w/v) BSA Fraction V in PBST 
EGF dilution buffer 10 mM acetic acid, 2 mg/mL BSA 
HBS (2×) 
50 mM HEPES, 280 mM NaCl, 12 mM D-glucose, 10 mM 
KCl, 1.5 mM Na2HPO4, pH 6.94-6.943 
Lower gel buffer 375 mM Tris-HCl, 0.1% (w/v) SDS, pH 8.8 
PBS 
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM 
KH2PO4 
PBST 0.1% (v/v) Tween-20 in PBS 
SDS-PAGE running buffer 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS 
SDS sample buffer 
10% (w/v) glycerol, 5% (v/v) 2-mercaptoethanol, 2.3% 
(w/v) SDS, 0.0625 M Tris, 0.1% (w/v) bromophenol blue 
Transfer buffer 
47 mM Tris, 39 mM glycine, 3.75% (w/v) SDS, 20% (v/v) 
methanol 
Upper gel buffer 125 mM Tris-HCl, 0.1% (w/v) SDS, pH 6.8 
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hours. An additional 6 mL of DMEM with 20% FBS was added to the plate without removing 
the transfection media and the cells were incubated at 37ºC and 5% CO2 overnight. On day 3, 
the media was replaced by the standard media (DMEM with 10% FBS). On day 4, the cells 
were serum starved overnight (16 to 24 hours). An EGF stimulation experiment (see section 
3.2.3 for detail) was carried out on day 5. 
3.2.1.2 HEK293T Cells Transfection 
HA-Ank105 was introduced into HEK293T cells by transient transfection using calcium 
phosphate. To optimize the amount of plasmid DNA used for transfection, HEK293T cells were 
split 1:5 into a 6-well plate in the morning of day 1. In the afternoon, different amounts (3 μg, 5 
μg, 6.25 μg, 7 μg and 9 μg) of pEGFP-C1 plasmid were added to 120 μL 265 mM CaCl2 and 
125 μL 2×HBS. After 20 minutes incubation at room temperature, the mixture was added 
drop-wise to the cells with existing media. Then the cells were incubated at 37ºC and 5% CO2 
overnight. In the morning of day 2, the media was removed, and the cells were washed and fed 
with standard media (DMEM/F-12 with 10% FBS). To monitor GFP expression, the cells were 
photographed using a fluorescence microscope (Nikon TE300) on the third day. 
Once the optimal amount of plasmid DNA was determined, plasmids encoding HA or 
HA-Ank105 were transfected into the cells. For each 10 cm plate, the transfection solution 
consisted of 30 μg pHA3 or pHA3-Ank105 plasmid DNA, 720 μL 265 mM CaCl2 and 750 μL 
2×HBS. The cells were transfected according to the protocol described above. In the afternoon 
of day 2, the cells were serum starved for 16 hours. An EGF stimulation experiment (see 
section 3.2.3 for detail) was carried out on day 3. 
3.2.2 Transduction with Adenovirus Vector 
In order to get high expression of ankyrin105 in MCF10A, MDA-MB-231 and AU565 
cells, adenovirus transduction was used. According to the protocol from Vector Core 
(www.med.umich.edu/vcore), the cells should be about 50% confluent before the transduction 
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carried out. So we needed to optimize the number of cells plated to make sure the cells would 
be about 50% confluent for the next day. The cells from different cell lines were counted by 
Coulter Particle Count and Size Analyzer (Beckman Coulter Z2) and different numbers of cells 
were plated in 6-well plates. By observing the plates on the next day, we could decide the 
numbers of cells needed for 50% confluent in 6-well plates, which were listed in Table 3.6. The 
numbers of cells for 10 cm plates were calculated based on the relative surface areas. 
Table 3.6 The numbers of cells for 50% confluent in 6-well plates and 10 cm plates 
Cell Line 6-well Plate 10 cm Plate 
MCF10A 7.5×10
4
 4.42×10
5
 
MDA-MB-231 3×10
5
 1.77×10
6
 
AU565 7.5×10
4
 4.42×10
5
 
To determine how much adenovirus was required to obtain high protein expression, 
different multiplicities of infection (MOIs) were tested. The appropriate numbers of cells from 
3 cell lines were plated in 6-well plates the day before transduction. The cells were about 50% 
confluent by the next day. The adenovirus was thawed on ice and 1:10 diluted in either PBS or 
cell culture media. The amount of adenovirus needed for a particular MOI was calculated from 
the following formula: Volume (μL) = (number of cells) × (desired MOI) / (PFU/μL). The 
different volumes of diluted adenovirus were added to cell culture media to make the total 
volume of 350 μL for each well. After aspirating existing media, the 350 μL of transduction 
media was added to each well and the cells were incubated at 37ºC for 1 hour. During the 
incubation, the plates were rocked every 10 to 15 minutes. Then the transduction media was 
replaced by the standard cell culture media and the cells were placed back to the incubator. The 
cells were observed using a fluorescence microscope each day up to 5 days post-transduction to 
monitor GFP expression in order to decide the optimal conditions. 
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For the transduction experiments performed in 10 cm plates in order to test ankyrin105 
function, the one hour adenovirus incubation using the optimal MOI was carried out as 
mentioned above. The transduction media for each plate was 2 mL. The cells were serum 
starved 16 to 24 hours on the fourth day post-transduction and an EGF stimulation experiment 
(see section 3.2.3 for detail) was carried out on the fifth day. 
Special safety precautions were used when working with adenovirus. Biosafety Level 2 
rules in the Biosafety Manual and Hazardous Waste Disposal Manual were followed. The 
biohazard signs were placed on BSC and incubator. All the experiments that required 
adenovirus were done in BSC. Two pairs of gloves and a lab coat were worn when handling 
adenovirus. After the experiment, waste solution was inactivated with 10% bleach for 15 
minutes and then discarded. The glass pipettes were soaked in 10% bleach for 15 minutes 
before sent for washing and sterilization. All other waste, including plates, tubes, plastic 
pipettes tips, gloves, etc., were decontaminated with 10% bleach for 15 minutes and then 
disposed in the biohazard bin. The BSC working area was also decontaminated with 10% 
bleach for 15 minutes and then wiped down with distilled water and 80% ethanol. 
3.2.3 Growth Factor Stimulation 
    To characterize ankyrin105 function during the degradation of EGFR and downregulation 
of downstream signaling pathways in response to EGF stimulation, the cells were treated with 
EGF in a time course experiment. Before the experiment, the cells were about 80% to 90% 
confluent. The cells were serum starved for 16 to 24 hours using starving media (all other 
components for the standard cell culture media but with only 0.5% serum). Then the media was 
replaced by 3 mL stimulation media containing 80 nM EGF (diluted in EGF dilution buffer first) 
and the cells were incubated at 37ºC for indicated times in each experiment. Cells were lysed 
(see section 3.2.4 for detail) for further experiments. 
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3.2.4 Cell Lysate Preparation 
    After different treatments for various times, the cells were placed on ice and washed with 
cold PBS. For each 10 cm plate, 300 μL sodium dodecyl sulfate (SDS) sample buffer at 100ºC 
was used to collect the cells by scraping the plate. Then the cell lysates were boiled at 100ºC for 
5 minutes. Because the lysates were viscous and hard to pipette an accurate volume, the cell 
lysates were sonicated for 5 seconds using the output control at 2 by Sonifier (Branson 450 P/S 
BIO) before use or storage at -20ºC or -80ºC. The protein concentration was obtained by Lowry 
Assay using Total Protein Kit, Micro Lowry, Peterson’s Modification (Sigma TP0300). 
3.3 Protein Analysis 
3.3.1 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The cell lysates containing total protein were resolved by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then followed by Western blot 
analysis (see section 3.3.2 for detail). SDS-PAGE was carried out in Mini-PROTEIN 4-Gel 
Electrophoresis System (Bio-Rad 165). 1 mm or 1.5 mm gels were cast between two glass 
plates and 10-well or 15-well combs were used depending on the volumes of loaded proteins. 
The SDS-PAGE gel was composed of resolving gel and stacking gel. Depending on the 
molecular weights of the detected proteins, different percentages (7.5%, 10% or 15% (w/v)) of 
acrylamide solution (29.2:0.8 acrylamide:bisacrylamide) in lower gel buffer (LGB) were used 
for resolving gels. 0.16% (w/v) ammonium persulfate (APS) and 0.1% (w/v) 
N,N,N’,N’-tetramethylethylenediamine (TEMED) were added to facilitate gel polymerization. 
The stacking gel consisted of 4.5% acrylamide solution in upper gel buffer (UGB), 0.24% (w/v) 
APS and 0.1% (w/v) TEMED (Laemmli, 1970). After the gels polymerized, the Prestained 
Protein Ladder (Fermentas SM0671) and cell lysates containing the same amounts of total 
protein were loaded on the gels. The electrophoresis was performed in running buffer at a 
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constant voltage of 180 V for about 1 hour until the bromophenol blue went off the bottom of 
the gel. 
3.3.2 Western Blot Analysis 
The gel was soaked in transfer buffer for 15 minutes on the rocker at a low speed. During 
this time, one piece of nitrocellulose membrane (Whatman BA85 10401196) was soaked in 
distilled water and 6 pieces of 3 MM filter paper (Whatman 3030-700) were soaked in transfer 
buffer for each gel. Three pieces of 3 MM paper, the SDS-PAGE gel, nitrocellulose membrane 
and 3 pieces of 3 MM paper were placed in the Semi-Dry Blotting Apparatus (Fisher 
FB-SDB-2020) following the order from bottom to top. Each gel was transferred at a constant 
current of 450 mA for 30 minutes. 
Nitrocellulose membrane was incubated in blocking buffer for 1 hour at room temperature 
or overnight at 4ºC on the rocker. Primary antibody, which was made in blocking buffer, was 
added and incubated for 1 hour at room temperature or overnight at 4ºC on the rocker. The blot 
was washed 4 times with PBST for 5 minutes each on the rocker. It was incubated in an 
infrared dye-labeled secondary antibody for 1 hour at room temperature or overnight at 4ºC on 
the rocker. The blot was washed 4 times with PBST for 5 minutes each again and rinsed in PBS 
to remove the tween. During the incubation with secondary antibody and the washing steps 
thereafter, the blot was covered with tinfoil to avoid the light. The blot was scanned using an 
Odyssey Infrared Imaging System (LI-COR 9201-01).  
3.3.3 Flow Cytometry 
Flow cytometry is a fluorescence-activated cell sorting technique to measure cell number, 
size and various properties in a flow system. The directly fluorescent-labeled cellular 
components or fluorescent-labeled antibodies against cellular proteins can be detected by the 
measuring the scattered light and fluorescent light (Bohn, 1980; Wilkerson, 2012). For the 
study of internalization of cell surface receptors in this thesis, flow cytometry was a very useful 
49 
 
approach for analyzing and quantifying cell surface ErbB2 levels. 
Geldanamycin (EMD 345805) was dissolved in dimethyl sulfoxide (DMSO) to a 
concentration of 1 mM and stored at -20ºC. Herceptin (Roche) was dissolved in water to a 
concentration of 10 mg/mL and stored at -80ºC. AU565 cells were treated with 1 μM 
geldanamycin or 10 μg/mL herceptin for the indicated times in different experiments (see 
section 4.6.3 and 4.6.5 for detail). 
After different treatments, the media was removed and the cells were washed once with 
PBS. The cells from each 10 cm plate (about 1×10
6 
cells) were trypsinized by 0.05% 
Trypsin/EDTA/PBS and collected in 5 mL standard cell culture media. Then the cells were 
centrifuged for 5 minutes at 290×g (Eppendorf 5810R) at 4ºC. The supernatant was aspirated 
and the pellet was resuspended in 100 μL flow cytometry staining buffer (eBioscience 00-4222) 
for blocking. After 15 minutes at 4ºC on the rocker, the cell suspension was centrifuged for 5 
minutes at 371×g (Eppendorf 5415R) at 4ºC. The pellet was resuspended in 100 μL staining 
buffer containing 0.5 μg Neu antibody (9G6). After 30 minutes at 4ºC on the rocker, the cell 
suspension was centrifuged for 5 minutes at 371×g at 4ºC. The pellet was resuspended in 1 mL 
PBS to wash away any excess primary antibody. The washing process was repeated 3 times. 
The pellet was resuspended in 100 μL staining buffer containing 0.5 μg phycoerythrin (PE) - 
conjugated secondary antibody and incubated for 30 minutes at 4ºC on the rocker. The same 
steps were used to wash away any excess secondary antibody. During the incubation with 
secondary antibody and the washing steps thereafter, the cell suspension was covered with 
tinfoil to protect from light. The pellet was resuspended in 1 mL of 1% paraformaldehyde and 
could be stored at 4ºC for 1 week. Samples were analyzed by flow cytometry (Beckman Coulter 
Epics XL) using FlowJo software (version 8.8.6). 
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4.0 RESULTS 
4.1 Ankyrin3, EGFR and ErbB2 Expression in Selected Cell Lines 
It has been shown that overexpression of the small isoforms of ankyrin3 (120 kDa and 105 
kDa) can stimulate the downregulation of the PDGFR (and its signaling) via the lysosomal 
degradation pathway in NIH 3T3 cells (Ignatiuk et al., 2006). Now we performed a similar 
study of the effect of ankyrin105 on EGFR degradation. Before the study was carried out, we 
tested the endogenous expression of ankyrin3 in COS-1, HEK293T, MCF10A, MDA-MB-231 
and AU565 cells, which were the model cell lines chosen for the study. 
For this experiment, cells from the five selected cell lines were collected in SDS sample 
buffer. The whole cell lysates were resolved by SDS-PAGE, transferred to nitrocellulose 
membranes and probed with antibodies against ankyrin3, EGFR, ErbB2 and GAPDH (Figure 
4.1). Then infrared dye-labeled secondary antibodies were used to detect bound antibodies 
using an Odyssey Infrared Imaging System. For the blots probed with ankyrin3 and GAPDH, 
100 μg of protein was loaded. For the blots probed with EGFR and ErbB2, 50 μg of protein was 
loaded. 
Different cell lines expressed different isoforms of ankyrin3 (Figure 4.1). The prestained 
markers used are only an approximation of the molecular weights. Besides, ankyrin3 isoforms 
may have some translational modifications that may slightly change their sizes. So we indicated 
the molecular weights of ankyrin3 isoforms according to estimation in Figure 4.1. In COS-1, 
HEK293T and AU565 cells, there were relatively low expression of the large isoform of 
ankyrin3 and high expression of ankyrin120 and ankyrin105. In MCF10A and MDA-MB-231 
cells, almost no major isoforms of ankyrin3 were detected. However, MDA-MB-231 cells 
showed a relatively low level of ankyrin120 and ankyrin105. The immunoblot for GAPDH 
antibody was shown as a loading control to make sure that similar amounts of total protein were 
loaded. In conclusion, there was high endogenous ankyrin105 expression in COS-1, HEK293T 
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Figure 4.1 Ankyrin3, EGFR and ErbB2 expression in selected cell lines. Cells were 
collected in SDS sample buffer. The whole cell lysates were resolved by SDS-PAGE, 
transferred to nitrocellulose membrane and probed with the indicated antibodies. Then infrared 
dye-labeled secondary antibodies were used and bound antibodies were visualized using an 
Odyssey Infrared Imaging System. For the blots probed with ankyrin3 and GAPDH, 100 μg of 
protein was loaded. For the blots probed with EGFR and ErbB2, 50 μg of protein was loaded. 
Prestained molecular weight markers were shown on the left and their approximate molecular 
weights were indicated. Representative blots were shown for one of two independent 
experiments. 
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and AU565 cells and low endogenous ankyrin105 expression in MDA-MB-231 cells. 
As shown in Figure 4.1, these selected cell lines all expressed EGFR, but ErbB2 was only 
detected in AU565 cells at a relatively high level. In COS-1, MDA-MB-231 and AU565 cells, 
EGFR levels were relatively high compared to other 2 cell lines. MCF10A cells expressed less 
EGFR and HEK293T cells had the least EGFR expression among 5 cell lines. 
4.2 Overexpression of Ankyrin105 in COS-1 Cells 
COS-1 cells are transformed African green monkey kidney cells and are commonly used 
for transfection to obtain high transient expression of recombinant proteins. COS-1 cells have 
SV40 genomic insertion which can express large T antigen. This promotes the plasmids 
containing an SV40 replication origin to replicate by inactivating tumor suppressors and 
regulating cyclins and cyclin-dependent kinases (Ali and DeCaprio, 2001; Asano et al., 1985). 
In order to get high expression of ankyrin105 in COS-1 cells, we transfected the cells with 
pHA3-Ank105 plasmid (containing an SV40 replication origin) using Lipofectamine reagent. 
After serum starvation for 16 to 24 hours, COS-1 parental cells and cells transfected with 
different amounts (3 μg and 6 μg) of HA-Ank105 plasmid DNA were treated with EGF in a 
time course experiment (0 minute, 30 minutes and 120 minutes). The cell lysates (25 μg of 
protein/lane) were analyzed by Western blot with EGFR, pTyr, pAkt/Akt, pMAPK/MAPK, HA 
and GAPDH antibodies. 
In parental cells, EGFRs were degraded in response to EGF stimulation (Figure 4.2). The 
activation of EGFRs can be measured by the phosphotyrosine level using an antibody specific 
for phosphotyrosine residues. The pTyr blot showed the activation of EGFRs, which was 
slightly downregulated upon EGF stimulation in the time course experiment up to 120 minutes. 
The immunoblot for HA antibody was used to confirm the expression of HA-Ank105 for 
different time points. HA-Ank105 expression did not have an impact on basal and activated 
EGFR levels. In parental and ankyrin105-expressing cells, it was surprising that pAkt levels 
were so low at 30 minutes and so high at 120 minutes, which might suggest the upregulation of 
PI3K-Akt pathway. pMAPK results were fairly typical that MAPK was activated in response to 
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Figure 4.2 Effect of ankyrin105 overexpression on EGFR and signaling pathways in 
COS-1 cells. Time course of EGF stimulation (0 min, 30 min and 120 min) in COS-1 parental 
cells and cells transfected with different amounts of HA-Ank105 plasmid DNA was carried out. 
The cell lysates (25 μg of protein/lane) were analyzed by Western blot with EGFR, pTyr, 
pAkt/Akt, pMAPK/MAPK, HA and GAPDH antibodies. Representative blots were shown for 
one of three independent experiments. 
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EGF stimulation and showed a sustained activation. The immunoblot for GAPDH antibody was 
shown as a loading control. In summary, overexpression of ankyrin105 did not enhance EGFR 
degradation or downregulation of EGFR signaling pathways in COS-1 cells. 
4.3 Overexpression of Ankyrin105 in HEK293T Cells 
4.3.1 Optimization of Calcium Phosphate Transfection Efficiency 
HEK293T cells are transformed human embryonic kidney cells and are easily transfected 
by various methods, such as calcium phosphate. Like COS-1 cells, HEK293T cells also have 
SV40 genomic insertion, so they could take the advantage of large T antigen to help the 
plasmids containing SV40 replication origin to multiply. 
Calcium phosphate transfection of HEK293T cells can generate relatively high transient 
expression levels, but the amount of plasmid DNA used for transfection needs to be optimized. 
In this experiment, HEK293T cells were transfected with different amounts (3 μg, 5 μg, 6.25 μg, 
7 μg and 9 μg) of pEGFP-C1 plasmid (containing SV40 replication origin) in a 6-well plate 
using calcium phosphate transfection methods. After 16 hours incubation, the media containing 
pEGFP-C1 plasmid was removed, and then the cells were washed and fed. To monitor GFP 
expression, the cells were photographed 2 days post-transfection under fluorescence 
microscopy. We compared the cells using fluorescent (Figure 4.3 left panel) and bright field 
modes (Figure 4.3 right panel). 
For different transfection conditions (i.e. the amounts of plasmid DNA), the numbers of 
total cells were similar (Figure 4.3 right panel). The number of cells that expressed GFP 
representing transfection efficiency increased with the increasing amounts of GFP DNA up to 5 
μg (Figure 4.3 left panel). When the DNA amount was greater than 5 μg, the number of 
GFP-expressing cells decreased, which suggested that transfection efficiency gradually 
decreased with the increasing DNA amount. It seemed that large amounts of DNA were toxic to 
the cells. The GFP expression was optimal using 5 μg plasmid DNA, which was used for 
further experiments. 
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Figure 4.3 Optimization of calcium phosphate transfection efficiency in HEK293T cells. 
HEK293T cells were transfected with different amounts of GFP DNA in a 6-well plate using 
calcium phosphate. Cells were photographed 2 days post-transfection to monitor GFP 
expression under fluorescence microscopy using fluorescent (left panel) and bright field modes 
(right panel). Representative photos were shown for one of two independent experiments.  
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4.3.2 Effect of Ankyrin105 Overexpression on Receptor Tyrosine Kinases and Signaling 
Pathways in HEK293T Cells 
To address ankyrin105 function in the degradation of EGFR in HEK293T cells, the cells 
were transfected using optimized amount (30 μg for 10 cm plate) of pHA3 and pHA3-Ank105 
plasmids (both containing an SV40 replication origin) by calcium phosphate. The cells 
transfected with pHA3 plasmid were used as controls to make sure that calcium phosphate 
transfection process and HA expression wound not impact the properties of the cells. After the 
transfection media was removed and the cells were washed and fed for 8 hours, the cells were 
serum starved for 16 hours. Then HEK293T parental cells and cells transfected with HA and 
HA-Ank105 were treated in a time course EGF stimulation experiment. The cell lysates were 
analyzed by Western blot with the indicated antibodies. For the blots probed with EGFR and 
pTyr, 200 μg of protein was loaded. For other blots, 25 μg of protein was loaded. This is 
because HEK293T cells express a relatively low level of EGFR compared to other selected cell 
lines (Figure 4.1), which makes it difficult to detect the changes in EGFR levels during the 
stimulation. 
In parental cells, EGFRs were rapidly degraded in response to EGF stimulation (Figure 
4.4). After 30 minutes, there were almost no EGFRs left. The corresponding phosphotyrosine 
blots suggested the downregulation of activated EGFRs and the weak bands were probably due 
to the low EGFR expression in this cell line. The immunoblots for HA antibody were used to 
confirm that the transfection efficiency was similar among the different time point samples. In 
ankyrin105-expressing cells, both EGFR and activated EGFR levels decreased in the time 
course treatment. However, there was no significant difference in EGFR degradation when 
comparing to parental cells and HA-expressing cells. In each of the three cell lines, PI3K-Akt 
pathway showed a sustained activation, while Ras-MAPK pathway showed a decreased 
activation in signaling as compared to earlier time points in response to EGF stimulation. Akt 
activation was upregulated in both HA and HA-Ank105 transfected cells compared to parental 
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Figure 4.4 Effect of ankyrin105 overexpression on EGFR and signaling pathways in 
HEK293T cells. Time course of EGF stimulation (0 min, 10 min, 30 min, 60 min, 120 min and 
240 min) in HEK293T parental cells and cells transfected with HA and HA-Ank105 was 
carried out. The cell lysates were analyzed by Western blot with EGFR, pTyr, pAkt/Akt, 
pMAPK/MAPK, HA and GAPDH antibodies. For the blots probed with EGFR and pTyr, 200 
μg of protein was loaded. For other blots, 25 μg of protein was loaded. Representative blots 
were shown for one of three independent experiments. 
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cells. The immunoblots for GAPDH antibody were shown as a loading control. In conclusion, 
overexpression of ankyrin105 did not enhance EGFR degradation or downregulation of EGFR 
signaling pathways in HEK293T cells. 
4.4 Overexpression of Ankyrin105 in MCF10A Cells 
4.4.1 Optimization of Adenovirus Transduction Efficiency in MCF10A Cells 
MCF10A cells are immortalized human breast cells, but are not tumorigenic or 
transformed (Debnath et al., 2003; Imbalzano et al., 2009). In order to get high expression of 
ankyrin105, an adenovirus vector was used because it could deliver the recombinant viral DNA 
into the nucleus of host cell and replicate in both dividing and non-dividing cells (Kawabata et 
al., 2006; Tashiro et al., 2010). 
To decide how much adenovirus was required to obtain high HA-Ank105 expression, 
different MOIs of Ad-GFP were tested first. MCF10A cells (7.5×10
4
) were plated in 6-well 
plate the day before transduction. The cells were about 50% confluent by the next day. The 
cells were incubated in adenoviral media containing Ad-GFP at designed MOIs (50, 100 and 
200) for 1 hour. A second transduction was performed 2 days after the first transduction. The 
cells expressing GFP and not expressing GFP were counted under fluorescence and bright field 
microscopy 5 days after the first transduction to determine transduction efficiency. 
The transduction efficiency was shown as a percentage and it increased with increasing 
MOI (Table 4.1). At an MOI 200, more than 85% of cells were transduced. However, 
transducing the cells twice did not significantly improve the transduction efficiency. Therefore, 
an MOI 200 and single transduction were selected for further experiments to balance the 
transduction efficiency with the amount of adenovirus used. 
To determine the expression of transduced viral DNA, MCF10A cells were transduced 
with Ad-GFP+HA-Ank105 at an MOI 200. This adenovirus vector coexpresses GFP and 
HA-Ank105. The cells were photographed under fluorescence microscope every day 
post-transduction up to 5 days to monitor GFP expression (Figure 4.5 A). The cell lysates from 
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Table 4.1 Optimization of adenovirus transduction efficiency in MCF10A cells. MCF10A 
cells were transduced once or twice (2 days after the first transduction) by a control adenovirus 
expressing GFP at different MOIs. Cells expressing GFP and not expressing GFP were counted 
5 days after the first transduction. Similar results were obtained in two independent 
experiments. 
 
 
MOI 
(transduction once) 
Efficiency MOI 
(transduction twice) 
Efficiency 
50 68% 50/50 72% 
100 77% 100/100 82% 
200 85% 200/200 88% 
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Figure 4.5 Optimization of adenovirus transduction efficiency in MCF10A cells. MCF10A 
cells were transduced by the adenovirus coexpressing GFP and HA-Ank105 at an MOI 200. A, 
The cells were photographed under fluorescence microscopy each day after transduction to 
monitor GFP expression. B, The cell lysates (25 μg of protein/lane) were analyzed by Western 
blot with GFP, HA and GAPDH antibodies. Representative results were shown for one of two 
independent experiments.  
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each day post-transduction were analyzed by Western blot with GFP, HA and GAPDH 
antibodies (Figure 4.5 B). The control sample was MCF10A whole cell lysate. 
Both the number of cells expressing GFP and the levels of GFP expression increased with 
days of post-transduction up to 5 days (Figure 4.5 A). The Western blot results further 
confirmed increasing levels of GFP and HA-Ank105 expression after transduction (Figure 4.5 
B). The cells would be too confluent 5 days post-transduction. Therefore, further experiments 
were carried out 4 or 5 days post-transduction to get high protein expression and not to lose the 
cell properties. 
4.4.2 Effect of Ankyrin105 Overexpression on Receptor Tyrosine Kinases and Signaling 
Pathways in MCF10A Cells 
To characterize ankyrin105 function in the degradation of EGFR in MCF10A cells, GFP 
and GFP+HA-Ank105 were transduced into the cells by adenovirus using the optimal 
conditions determined in previous experiments. The cells transduced with Ad-GFP were used as 
a control to make sure that the adenovirus transduction process and GFP expression wound not 
impact the properties of the cells. The cells were serum starved for 16 to 24 hours on the fourth 
day post-transduction. Then MCF10A parental cells, Ad-GFP transduced cells and 
Ad-GFP+HA-Ank105 transduced cells were treated with EGF in a time course experiment. The 
cell lysates were analyzed by Western blot with the indicated antibodies. 
As shown in Figure 4.6, EGFRs were rapidly degraded in response to EGF stimulation in 
parental cells. After 60 minutes, EGFRs were barely detected. GFP blots confirmed the 
transduction efficiency and HA blots confirmed the expression of HA-Ank105 was similar 
among the different time points. In both transduced cells, the rate of EGFR degradation was 
slower than that in parental cells. The corresponding phosphotyrosine blots indicated the 
downregulation of activated EGFRs. In all three cell lines, both PI3K-Akt pathway and 
Ras-MAPK pathway showed a decreased activation in signaling as compared to earlier time 
points upon EGF stimulation, which indicated that the downregulation of downstream signaling 
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Figure 4.6 Effect of ankyrin105 overexpression on EGFR and signaling pathways in 
MCF10A cells. Time course of EGF stimulation (0 min, 10 min, 30 min, 60 min, 120 min and 
240 min) in MCF10A parental cells, cells transduced with adenovirus GFP control and with 
adenovirus GFP+HA-Ank105 was carried out. The cell lysates (25 μg of protein/lane) were 
analyzed by Western blot with EGFR, pTyr, pAkt/Akt, pMAPK/MAPK, GFP, HA and GAPDH 
antibodies. Representative blots were shown for one of three independent experiments. 
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pathways were not affected by ankyrin105. The immunoblots for GAPDH antibody were 
shown as a loading control. These results suggested that overexpression of ankyrin105 did not 
enhance EGFR degradation or downregulation of EGFR signaling pathways in MCF10A cells. 
4.5 Overexpression of Ankyrin105 in MDA-MB-231 Cells 
4.5.1 Optimization of Adenovirus Transduction Efficiency in MDA-MB-231 Cells 
MDA-MB-231 cells are highly invasive and metastatic human breast cancer cells (Laezza 
et al., 2012). In order to get high expression of ankyrin105, an adenovirus vector was used to 
deliver the desired gene. 
To decide how much adenovirus was required to obtain high HA-Ank105 expression, 
different MOIs were first tested. MDA-MB-231 cells (3×10
5
) were plated in a 6-well plate the 
day before transduction. The following day 50% confluent cells were incubated in adenoviral 
media containing Ad-GFP at designed MOIs (100, 200 and 500) for 1 hour. Then the cells were 
photographed using fluorescence microscopy with both fluorescent and bright field every day 
post-transduction up to 4 days to determine transduction efficiency and GFP expression (Figure 
4.7). Both the number of cells expressing GFP and GFP expression increased with the 
increasing MOIs and days of post-transduction up to 4 days. On the fourth day, transduction 
efficiency and GFP expression between MOI 200 and MOI 500 were almost the same and 
majority of the cells were transduced at MOI 200. Therefore, a higher MOI was not necessary 
and an MOI 200 was chosen for further experiments. 
4.5.2 Effect of Ankyrin105 Overexpression on Receptor Tyrosine Kinases and Signaling 
Pathways in MDA-MB-231 Cells 
To determine ankyrin105 function in the degradation of EGFR in MDA-MB-231 cells, 
GFP and GFP+HA-Ank105 were transduced into the cells by adenovirus at an MOI 200. The 
cells were serum starved for 16 to 24 hours on the fourth day post-transduction. Then 
MDA-MB-231 parental cells, Ad-GFP transduced cells and Ad-GFP+HA-Ank105 transduced 
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Figure 4.7 Optimization of adenovirus transduction efficiency in MDA-MB-231 cells. 
MDA-MB-231 cells were transduced by a control adenovirus (Ad-GFP) at different MOIs. 
Cells were photographed every day post-transduction up to 4 days to monitor GFP expression. 
Representative photos were shown for one of two independent experiments. 
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cells were treated with EGF for different times. The cell lysates were analyzed by Western blot 
with the indicated antibodies. 
Surprisingly, EGFRs were not degraded in response to EGF stimulation in parental cells 
(Figure 4.8). However, the corresponding phosphotyrosine blots showed the downregulation of 
activated EGFRs, which was not correlated to EGFR level. In both transduced cells, EGFR 
level did not change, which was almost the same as that in parental cells. The activated EGFRs 
downregulated very fast and were hardly detected even after 10 minutes of stimulation. In all 
three cell lines, PI3K-Akt pathway showed prolonged activation, while Ras-MAPK pathway 
showed a decreased activation in signaling as compared to earlier time point during EGF 
stimulation. But the downregulation of activated MAPK was facilitated in both transduced cells 
compared to parental cells. The immunoblots for GFP, HA and GAPDH antibodies were shown 
as control. Overexpression of ankyrin105 did not enhance EGFR degradation or 
downregulation of EGFR signaling pathways in MDA-MB-231 cells. 
4.6 Overexpression of Ankyrin105 in AU565 Cells 
4.6.1 Optimization of Adenovirus Transduction Efficiency in AU565 Cells 
AU565 cells are human breast cancer cells and express high levels of both EGFR and 
ErbB2 (Figure 4.1) (Huang et al., 2010; Neve et al., 2006). Similar to other human breast cell 
lines, adenovirus vector was transduced into cells to get high expression of ankyrin105. 
To optimize how much adenovirus was required for high HA-Ank105 expression, 
different MOIs were tested. AU565 cells (7.5×10
4
) were plated in a 6-well plate the day before 
transduction. The following day 50% confluent cells were incubated in adenoviral media 
containing Ad-GFP control at designed MOIs for 1 hour. Then the cells were photographed 
using fluorescence microscopy every day post-transduction up to 4 days to determine the 
optimal conditions (Figure 4.9). Both the number of cells expressing GFP and GFP expression 
increased with the increasing MOIs and days of post-transduction up to 4 days. There were not 
significant differences in transduction efficiency and GFP expression between MOI 200 and 
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Figure 4.8 Effect of ankyrin105 overexpression on EGFR and signaling pathways in 
MDA-MB-231 cells. Time course of EGF stimulation (0 min, 10 min, 30 min, 60 min, 120 min 
and 240 min) in MDA-MB-231 parental cells, cells transduced with adenovirus GFP control 
and with adenovirus GFP+HA-Ank105 was carried out. The cell lysates (25 μg of protein/lane) 
were analyzed by Western blot with EGFR, pTyr, pAkt/Akt, pMAPK/MAPK, GFP, HA and 
GAPDH antibodies. Representative blots were shown for one of three independent experiments. 
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Figure 4.9 Optimization of adenovirus transduction efficiency in AU565 cells. AU565 cells 
were transduced by a control adenovirus (Ad-GFP) at different MOIs. Cells were photographed 
every day post-transduction up to 4 days to monitor GFP expression. Representative photos 
were shown for one of two independent experiments. 
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MOI 500. So an MOI 200 was chosen for the further study as previous experiments. 
4.6.2 Effect of Ankyrin105 Overexpression on Receptor Tyrosine Kinases and Signaling 
Pathways in AU565 Cells 
To identify ankyrin105 function in the degradation of EGFR in AU565 cells, GFP and 
GFP+HA-Ank105 were transduced into the cells by adenovirus at an MOI 200. The cells were 
serum starved for 16 to 24 hours on the fourth day post-transduction. Then AU565 parental 
cells, Ad-GFP transduced cells and Ad-GFP+HA-Ank105 transduced cells were stimulated 
with EGF for indicated times. The cell lysates were analyzed by Western blot with the indicated 
antibodies. 
In parental cells, both EGFRs and ErbB2 were not degraded in response to EGF 
stimulation (Figure 4.10). There was a basal level of activated EGFRs prior to EGF stimulation 
and activated EGFRs were slowly downregulated. Cells transduced with Ad-GFP+HA-Ank105 
did not show significant differences for EGFR, activated EGFR and ErbB2 compared to 
parental cells and control adenovirus transduced cells. The downregulation of EGFR 
downstream signaling (pAkt/Akt, pMAPK/MAPK) was promoted in both Ad-GFP and 
Ad-GFP+HA-Ank105 transduced cells compared to parental cells. GFP, HA and GAPDH blots 
were shown as control. In summary, overexpression of ankyrin105 did not enhance EGFR 
degradation or downregulation of EGFR signaling pathways in AU565 cells. 
4.6.3 Effect of Geldanamycin Treatment on Receptor Tyrosine Kinases 
ErbB2 can heterodimerize with other members of the EGFR subfamily without growth 
factors (Burgess et al., 2003). It is shown to be internalization resistant (Hommelgaard et al., 
2004). So overexpression of ErbB2 in AU565 cells may block internalization, endocytosis and 
degradation of receptors. In order to downregulate ErbB2 and reduce ErbB2-mediated blocking 
of EGFR degradation, an Hsp90 inhibitor geldanamycin was used. 
To investigate to what extent geldanamycin can induce internalization of ErbB2, AU565 
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Figure 4.10 Effect of ankyrin105 overexpression on ErbB2, EGFR and signaling pathways 
in AU565 cells. Time course of EGF stimulation (0 min, 10 min, 30 min, 60 min, 120 min and 
240 min) in AU565 parental cells, cells transduced with adenovirus GFP control and with 
adenovirus GFP+HA-Ank105 was carried out. The cell lysates (25 μg of protein/lane) were 
analyzed by Western blot with EGFR, ErbB2, pTyr, pAkt/Akt, pMAPK/MAPK, GFP, HA and 
GAPDH antibodies. Representative blots were shown for one of six independent experiments. 
 
70 
 
cells were treated with DMSO (control; Geldanamycin is made up in DMSO), GA (1 μmol/L), 
EGF or GA+EGF for different times (0 h, 2 h, 4 h, 6 h, 12 h and 24 h) at 37ºC. After fixation, 
the cells were incubated with an antibody specific to the extracellular domain of ErbB2. Then a 
PE-conjugated secondary antibody was added. Flow cytometry analysis was used to detect cell 
surface ErbB2 (Figure 4.11). 
    When incubated with DMSO or EGF for different times, the peak representing surface 
ErbB2 did not shift, which suggested that ErbB2 was not internalized (Figure 4.11 A). When 
treated with GA or GA+EGF for more than 4 hours, the shift to the left in the peak showed that 
geldanamycin induced a decrease in surface ErbB2. In Figure 4.11 B, the same flow cytometry 
data were analyzed by comparing different treatments at the same time point. It was much 
clearer that ErbB2 was internalized by geldanamycin treatment. However, there was not much 
difference between cells treated with GA alone and GA+EGF together. EGF did not promote 
geldanamycin-induced ErbB2 internalization. The flow cytometry data of cells and cells treated 
with only secondary antibody were shown as negative controls. The flow cytometry results 
confirmed that ErbB2 could be internalized upon geldanamycin treatment. 
To investigate to what extent geldanamycin could induce degradation of ErbB2, AU565 
cells were incubated with DMSO, GA, EGF or GA+EGF for various times. Cell lysates were 
analyzed by Western blot with EGFR, ErbB2 and GAPDH antibodies to detect the degradation 
of ErbB2 and EGFR. The immunoblot results showed that ErbB2 was degraded in response to 
geldanamycin treatment and EGFRs were also degraded in parallel with the decreased ErbB2 
levels (Figure 4.12). After 12 hours, most ErbB2 and EGFRs were degraded. Similar to flow 
cytometry results, DMSO or EGF treatment did not change the receptors level and GA+EGF 
treatment did not further facilitate the degradation of receptors. Therefore, geldanamycin 
induced degradation of ErbB2 and EGFR in AU565 cells. 
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Figure 4.11 Effect of geldanamycin on surface ErbB2 in AU565 cells. AU565 cells were 
incubated with DMSO, GA (1 μmol/L), EGF or GA+EGF for various times (0 h, 2 h, 4 h, 6 h, 
12 h and 24 h) at 37ºC. After fixation, the cells were incubated with an antibody specific to the 
extracellular domain of ErbB2. Then a PE-conjugated secondary antibody was added. Flow 
cytometry analysis was used to detect the amount of ErbB2 remaining at the plasma membrane. 
A, Data were analyzed by comparing different time points for the same treatment. B, Data were 
analyzed by comparing different treatments at the same time point. Representative results were 
shown for one of two independent experiments. 
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Figure 4.12 Effect of geldanamycin on ErbB2 and EGFR in AU565 cells. AU565 cells were 
incubated with DMSO, GA (1 μmol/L), EGF or GA+EGF for various times at 37ºC. The cell 
lysates (25 μg of protein/lane) were analyzed by Western blot with EGFR, ErbB2 and GAPDH 
antibodies to detect the degradation of ErbB2 and EGFR. Representative blots were shown for 
one of two independent experiments. 
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4.6.4 Effect of Geldanamycin Treatment on Receptor Tyrosine Kinases and Signaling 
Pathways in Ankyrin105 Overexpressing Cells 
Since geldanamycin induced degradation EGFR in AU565 cells, ankyrin105 was 
introduced into the cells before geldanamycin treatment to test whether overexpression of 
ankyrin105 could further downregulate EGFR in combination with geldanamycin. To perform 
the experiment, AU565 parental cells, cells transduced with adenovirus GFP control and with 
adenovirus GFP+HA-Ank105 were incubated with DMSO, GA, EGF or GA+EGF for various 
times. Then the cell lysates were analyzed by Western blot with the indicated antibodies. 
As shown in Figure 4.13, ankyrin105-expressing cells did not show an increase in EGFR 
degradation or activated EGFR downregulation compared to parental and control transduced 
cells. In addition, the downstream signaling pathways (pAkt/Akt, pMAPK/MAPK) were not 
impacted by ankyrin105 (Figure 4.14). These data indicated that overexpression of ankyrin105 
did not enhance EGFR degradation or downregulation of EGFR signaling pathways in AU565 
cells treated with geldanamycin which already downregulated ErbB2 and EGFR. 
4.6.5 Effect of Herceptin Treatment on Receptor Tyrosine Kinases 
A second method to downregulate ErbB2 was herceptin treatment. Herceptin is an 
anti-ErbB2 antibody, which binds to the extracellular domain of ErbB2. It can affect ErbB2 
structure and dimerization with other EGFR family members, and may facilitate internalization 
and degradation of the receptors (Singer et al., 2012; Tsang and Finn, 2012). 
AU565 cells were incubated with herceptin (10 μg/mL) and two different doses of EGF for 
various times at 37ºC. It has been demonstrated that receptors were endocytosed through a 
clathrin-dependent pathway when treated with low concentrations of EGF and the majority of 
EGFRs were internalized through a clathrin-independent pathway upon high concentrations of 
EGF stimulation (Sigismund et al., 2005). Flow cytometry analysis was used to detect the 
downregulation of ErbB2 from the plasma membrane. After treatment with herceptin, EGF and 
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Figure 4.13 Effect of ankyrin105 overexpression on ErbB2 and EGFR in AU565 cells 
treated with geldanamycin. AU565 parental cells, cells transduced with adenovirus GFP 
control and with adenovirus GFP+HA-Ank105 were incubated with DMSO, GA (1 μmol/L), 
EGF or GA+EGF for various times at 37ºC. The cell lysates (25 μg of protein/lane) were 
analyzed by Western blot with EGFR, ErbB2, pTyr, GFP and HA antibodies. Representative 
blots were shown for one of three independent experiments. 
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Figure 4.14 Effect of ankyrin105 overexpression on signaling pathways in AU565 cells 
treated with geldanamycin. AU565 parental cells, cells transduced with adenovirus GFP 
control and with adenovirus GFP+HA-Ank105 were incubated with DMSO, GA (1 μmol/L), 
EGF or GA+EGF for various times at 37ºC. The cell lysates (25 μg of protein/lane) were 
analyzed by Western blot with pAkt/Akt, pMAPK/MAPK and GAPDH antibodies. 
Representative blots were shown for one of three independent experiments. 
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herceptin+EGF for 24 hours, the cell lysates were analyzed by Western blot to detect the 
degradation of ErbB2 and EGFR. The data were quantified by normalizing the ErbB2 and 
EGFR bands intensity to GAPDH using Odyssey system. 
As shown in Figure 4.15 A, the peak representing surface ErbB2 shifted to the left to a 
small extent for all three treatments after a relatively long incubation time (24 hours), 
suggesting that herceptin induced a small amount of internalization of ErbB2. When comparing 
different treatments at the same time point, different doses of EGF did not enhance ErbB2 
downregulation from the plasma membrane (Figure 4.15 B). The flow cytometry data of cells 
and cells treated with only secondary antibody were shown as negative controls. The 
corresponding immunoblots for ErbB2 and EGFR antibodies showed that the receptors were 
degraded when incubated with herceptin, EGF or herceptin+EGF (Figure 4.16 A). As shown in 
Figure 4.16 B and C, the normalized ErbB2 and EGFR levels suggested that herceptin or EGF 
alone induced some decrease in ErbB2 and EGFR but EGF alone induced a larger decrease. 
Herceptin and EGF together could induce the degradation of more than 70% of the receptors 
after 24 hours, which was much greater than when treated with herceptin or EGF alone. In 
conclusion, herceptin partially facilitated ErbB2 internalization and improved ErbB2 and EGFR 
degradation. Due to the time constraints, this experiment was carried out only once. These 
promising effects should be validated with additional replicate experiments. In addition, the 
impact of ankyrin105 expression in combination with herceptin+/-EGF should be tested. We 
might observe that EGFRs are further degraded in ankyrin105-expressing AU565 cells treated 
with herceptin. 
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Figure 4.15 Effect of herceptin on surface ErbB2 in AU565 cells. AU565 cells were 
incubated with herceptin (10 μg/mL) and two different doses of EGF for various times at 37ºC. 
Flow cytometry analysis was used to detect the downregulation of ErbB2 from the plasma 
membrane. A, Data were analyzed by comparing different time points for the same treatment. B, 
Data were analyzed by comparing different treatments at the same time point. This experiment 
was carried out once.  
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Figure 4.16 Effect of herceptin on ErbB2 and EGFR in AU565 cells. AU565 cells were 
incubated with herceptin (10 μg/mL), EGF and herceptin+EGF for 24 h at 37ºC. A, the cell 
lysates (25 μg of protein/lane) were analyzed by Western blot with EGFR, ErbB2 and GAPDH 
antibodies to detect the degradation of ErbB2 and EGFR. B and C, Western blot data were 
quantified by normalizing the ErbB2 and EGFR bands intensity to GAPDH using Odyssey 
system. These preliminary results were observed from one experiment. 
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5.0 DISCUSSION 
5.1 Ankyrin3 Expression in Selected Cell Lines 
Ankyrin3 is the most widely distributed among ankyrin family. Different isoforms are 
expressed in different cell types (Cunha and Mohler, 2006; Rubtsov and Lopina, 2000). We 
focused on its smaller isoform ankyrin105 because it has been demonstrated that 
overexpression of ankyrin105 promoted lysosomal-mediated degradation of the PDGFR in NIH 
3T3 cells (Ignatiuk et al., 2006). The hypothesis of this project was that ankyrin105 would 
facilitate degradation of EGFR and enhance the downregulation of signaling pathways. 
Different cell types are thought to use different mechanisms for EGFR endocytosis and 
downregulation (Hendriks et al., 2003; Seto et al., 2002). Thus, we may observe different 
effects on EGFR levels upon ankyrin105 expression in different EGFR-expressing cell types. 
Therefore, five cell lines were chosen for this project. We first tested the endogenous expression 
of ankyrin105 in these selected cell lines. In COS-1, HEK293T and AU565 cells, there was 
relatively high expression of ankyrin120 and ankyrin105. Little or no ankyrin120 or ankyrin105 
was detected in MCF10A cells and little ankyrin120 or ankyrin105 was present in 
MDA-MB-231 cells. In all 5 cell lines, the expression of large ankyrin3 isoform was relatively 
low (Figure 4.1). Thus, the cell lines used contained different levels of ankyrin3, but 
predominantly presented the 120 kDa and 105 kDa smaller isoforms when ankyrin3 was 
expressed. However, when we introduced ankyrin105 into each cell type during this study, we 
could not rule out the possibility that endogenous ankyrin105 in COS-1, HEK293T and AU565 
cells might already facilitate the degradation of EGFR, such that adding more had little effect. 
In the two breast cancer cell lines used in this project, MDA-MB-231 is a triple-negative 
(ER-, PR- and ErbB2-) breast cancer cell line (Tate et al., 2012), and AU565 is an 
ErbB2-positive (ER- or PR- and ErbB2+) breast cancer cell line (Lam et al., 2008). Based on 
ankyrin105 and ErbB2 expression in the two breast cancer cell lines (Figure 4.1), it could 
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suggest that ErbB2-positive breast cancer cell lines express high levels of ankyrin105 whereas 
triple-negative breast cancer cell lines express little or no ankyrin105. This needs to be tested 
further by examining ankyrin105 expression in a wide variety of breast cancer cell lines. 
Ankyrin105 expression in ErbB2-positive breast cancer cell line that also overexpresses EGFR 
(i.e. AU565) may reflect a cellular response to these overexpressed RTKs as the cells attempt to 
reduce receptor levels. 
5.2 Overexpression of Ankyrin105 in Selected Cell Lines 
5.2.1 Optimization of Transfection and Transduction Efficiency 
In order to investigate the effect of overexpression of ankyrin105 on EGFR levels and 
downstream EGFR signaling, we needed transiently high expression of ankyrin105 during the 
time course of EGF stimulation. So we introduced ankyrin105 into 5 selected cell lines by 
either transfection of plasmid DNA or transduction using adenovirus. We optimized the 
conditions for calcium phosphate transfection and adenovirus transduction to get high 
expression of HA-Ank105. For calcium phosphate transfection, optimal amount of plasmid 
DNA was 30 μg for 10 cm plate (Figure 4.3). For adenovirus transduction, the optimal MOI of 
200 (Table 4.1, Figure 4.7 and 4.8) was determined and EGF stimulation was carried out 4 or 5 
days post-transduction (Figure 4.5). 
5.2.2 Effect of Ankyrin105 Overexpression on Receptor Tyrosine Kinases and Signaling 
Pathways 
Our laboratory has previously shown that overexpression of ankyrin105 promotes 
degradation of the basal PDGFRs and activated PDGFRs and causes a more sustained  
activation of the PI3K-Akt pathway, but does not affect the Ras-MAPK pathway in NIH 3T3 
cells (Ignatiuk et al., 2006). Ankyrin105 may regulate multiple RTKs in the same way. We did 
not observe similar results in EGFR degradation and downstream signaling pathway 
downregulation in the 5 selected cell lines that transiently overexpressed ankyrin105. 
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In COS-1, HEK293T and AU565 cells, the degradation of basal EGFRs and activated 
EGFRs was not facilitated and downregulation of PI3K-Akt and Ras-MAPK pathways was not 
affected by ankyrin105 overexpression (Figure 4.2, 4.4 and 4.10). Thus, overexpression of 
ankyrin105 did not enhance EGFR degradation or downregulation of EGFR signaling pathways 
in these 3 cell lines. However, these cell lines all expressed relatively high levels of endogenous 
ankyrin105, which might already enhance EGFR downregulation to a certain extent. The 
introduced ankyrin105 may not be able to further improve EGFR degradation. 
As compared to other selected breast cells, AU565 cells express high levels of ErbB2 
(Neve et al., 2006). Unlike other EGFR family members, ErbB2 has a constitutively exposed 
dimerization arm, which can heterodimerize with other members of the EGFR subfamily, such 
as EGFR, even in the absence of growth factors (Burgess et al., 2003). ErbB2 is known to be 
internalization resistant, so EGFR-ErbB2 heterodimers may persist and prolong activation of 
receptors and downstream signaling pathways (Hommelgaard et al., 2004). ErbB2 can also 
enhance the binding affinity of the ligand (e.g. EGF) to its dimeric receptor (e.g. EGFR) (Fuller 
et al., 2008). Therefore, the overexpression of ErbB2 in AU565 cells may block internalization, 
endocytosis and degradation of receptors and prolong signaling pathways. As shown in Figure 
4.10, EGFRs were not degraded upon EGF stimulation. This was probably because ErbB2 
heterodimerized with EGFRs and inhibited EGFR downregulation. Ankyrin105 could not 
impact EGFR degradation since EGFR-ErbB2 heterodimers were not internalized.  
We also observed that Akt activation was upregulated in both HA and HA-Ank105 
transfected HEK293T cells while Akt and MAPK activation were downregulated in both 
Ad-GFP and Ad-GFP+HA-Ank105 transduced AU565 cells, compared to their parental cells, 
respectively (Figure 4.4 and 4.10). For calcium phosphate transfection, the mechanism 
regulating the uptake of the precipitate containing calcium phosphate and DNA is still unknown 
(Batard et al., 2001; Kingston et al., 2001). For adenovirus transduction, the gene delivery is 
via episomal expression (Hendrie and Russell, 2005). Adenovirus uses both clathrin-mediated 
and caveolae-mediated endocytosis to enter the cells (Campos and Barry, 2007; Smith and 
82 
 
Helenius, 2004). The uptake of adenovirus results in induction of intracellular signaling, such as 
the activation of the Ras-MAPK pathway and the PI3K-Akt pathway (Greber, 2002; Liu and 
Muruve, 2003). Therefore, calcium phosphate transfection and/or adenovirus transduction 
processes might affect both endocytosis and intracellular signaling pathways in ways not well 
understood. 
In MCF10A and MDA-MB-231 cells, the degradation of basal EGFRs and activated 
EGFRs was not facilitated and downregulation of PI3K-Akt and Ras-MAPK pathways was not 
affected by ankyrin105 overexpression (Figure 4.6 and 4.8). Thus overexpression of 
ankyrin105 did not enhance EGFR degradation or downregulation of EGFR signaling pathways 
in these 2 cell lines as well as the other 3 tested cell lines. In MDA-MB-231 cells, EGFRs were 
not degraded in response to EGF stimulation, which suggested EGFR degradation pathway 
might be defective and this cell line was not suitable to study ankyrin105 effects on EGFR 
degradation. The downregulation of activated EGFRs and activated MAPK was facilitated in 
both Ad-GFP and Ad-GFP+HA-Ank105 transduced cells compared to parental cells. This also 
suggested that adenovirus transduction process might affect intracellular signaling pathways. 
There might be several reasons why ankyrin105 did not impact EGFR signaling. First, 
ankyrin105 may not regulate degradation of EGFR or enhance the downregulation of signaling 
pathways at all. Second, the selected cell lines had some limitations, such as endogenous 
ankyrin105 expression and ErbB2 expression, or may contain an intrinsic EGFR 
downregulation defect, which could block the effect of overexpressed ankyrin105. Third, the 
number of cell lines chosen for this study may not have been large enough to find cell lines that 
possessed the criteria necessary for ankyrin105 to play a role in EGFR signaling. Fourth, 
perhaps the transfection and/or transduction procedures temporarily interfered with ankyrin105 
effects by perturbing internalization, endocytosis and trafficking pathways such that stable cell 
lines expressing ankyrin105 will need to be tested well after transfection or transduction. The 
effect of ankyrin105 overexpression on RTKs and signaling pathways still remains unclear 
since only PDGFR degradation in NIH 3T3 cells and EGFR degradation in 5 selected cells 
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were tested. The effect of ankyrin105 might be cell type specific (NIH 3T3 cells, but not COS-1, 
HEK293T, MCF10A, MDA-MB-231 or AU565 cells) or RTK specific (PDGFR, but not 
EGFR). Further experiments need to be carried out to evaluate ankyrin105 overexpression in a 
variety of cell lines under stable cell line conditions.  
5.3 Effect of Cancer Therapeutics in AU565 Cells 
The high expression of ErbB2 in AU565 cells promotes EGFR-ErbB2 heterodimer 
formation (Fuller et al., 2008). Due to resistant internalization of ErbB2, the endocytosis of 
ErbB2-containing heterodimers is inhibited, which may result in upregulation of signaling 
pathways (Hommelgaard et al., 2004; Yarden and Sliwkowski, 2001). Overexpression of ErbB2 
in AU565 cells blocks degradation of EGFR, which makes it difficult to test ankyrin105 effect 
on EGFR and its downstream signaling. Therefore, ErbB2 needed to be downregulated before 
the study of ankyrin105 could be carried out. In this project, 2 drugs were used to facilitate 
ErbB2 downregulation. 
5.3.1 Effect of Geldanamycin Treatment on Receptor Tyrosine Kinases and Signaling 
Pathways 
Geldanamycin is an Hsp90 inhibitor. It can bind to and inactivate the conserved 
ATP/ADP-binding pocket of Hsp90, and destabilize Hsp90 client proteins (e.g. ErbB2, IR, p53, 
Akt and MEK) (Austin et al., 2004; Pedersen et al., 2009; Zuehlke and Johnson, 2010). To 
investigate internalization of ErbB2 by geldanamycin, flow cytometry analysis was used to 
measure cell surface ErbB2 (Figure 4.11). Geldanamycin induced a decrease in surface ErbB2 
and the internalization was increased as the incubation time was prolonged. EGF did not 
facilitate ErbB2 downregulation of surface ErbB2 or further improve geldanamycin-induced 
ErbB2 internalization. To investigate the degradation of ErbB2 by geldanamycin, Western blot 
analysis was used to detect the total levels of ErbB2 (Figure 4.12). It showed that both ErbB2 
and EGFRs were degraded in response to geldanamycin treatment. The EGFR degradation 
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resulted from the decreased ErbB2 levels after incubation with geldanamycin. Similarly, EGF 
treatment did not change the receptors level and GA+EGF treatment did not further promote the 
degradation of receptors. Therefore, as shown in the literature, geldanamycin could induce 
degradation of ErbB2. 
Then the ability of ankyrin105 overexpression to enhance receptors degradation in 
combination with geldanamycin treatment was assessed. Flow cytometry analysis was no 
longer suitable for this study. The fluorescent light from GFP (co-expressed by the adenovirus) 
in transduced cells had a certain degree of overlap with that from the PE signal, which made the 
PE peak shift to the left and show false positive results. As shown in Western blot results 
(Figure 4.13 and 4.14), ankyrin105 did not impact EGFR degradation or its downstream 
signaling pathways in geldanamycin-treated AU565 cells which already downregulated ErbB2 
and EGFR. These results suggested that overexpression of ankyrin105 did not further enhance 
EGFR degradation or downregulation of EGFR signaling pathways as the levels of EGFR were 
rapidly reduced at the same time as geldanamycin induced ErbB2 degradation. 
As an Hsp90 inhibitor, geldanamycin may promote degradation of Hsp90 client proteins 
including p53 and Akt that are important for multiple cellular processes. Thus, incubation of 
cells with geldanamycin has toxic side effects and may interrupt normal cellular mechanisms. 
Although geldanamycin can induce ErbB2 degradation, it is still not used for clinical cancer 
therapeutics mainly because of these toxicities. Perhaps testing lower concentrations of 
geldanamycin would reduce these toxicities and the addition of ankyrin105 expression could 
make it more selective for ErbB2 and EGFR degradation. 
5.3.2 Effect of Herceptin Treatment on Receptor Tyrosine Kinases 
Herceptin is a monoclonal antibody that binds the ErbB2 extracellular domain, blocks 
ErbB2-induced dimerization and inhibits intracellular tyrosine kinase activity (Hudis, 2007; 
Tsang and Finn, 2012). It can enhance ErbB2 internalization and degradation, and regulate 
intracellular downstream signaling pathways (Spector and Blackwell, 2009). As shown in 
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Figure 4.15, herceptin induced a small amount of internalization of ErbB2. Different doses of 
EGF did not have an effect on ErbB2 internalization in combination with herceptin. The 
Western blot results showed that both ErbB2 and EGFRs were degraded when incubated with 
herceptin, EGF or herceptin+EGF (Figure 4.16). Cells treated with both herceptin and EGF 
could induce much more degradation of the receptors compared to those treated with herceptin 
or EGF alone. These results suggested that herceptin improved ErbB2 and EGFR 
internalization and degradation. It was strange that the amount of ErbB2 degraded was more 
than internalized (Figure 4.15 and 4.16). These experiments only carried out once and replicate 
experiments are needed to confirm the conclusions. 
In clinical treatment, patients may become herceptin resistant (Gajria and Chandarlapaty, 
2011) and have some side effects such as cardiac toxicity, neutropenia and anemia (Chen et al., 
2011; Chien and Rugo, 2010). Besides, the full course of herceptin treatment is expensive. So 
new therapeutics may be developed by using less herceptin in combination with EGF based on 
the preliminary results of Figure 4.16. 
5.4 Future Directions 
    In this project, we performed growth factor stimulation to evaluate ankyrin105 effects on 
EGFR levels and intracellular signaling in 5 selected cell lines. Our goal was to reduce EGFR 
levels and signaling in breast cancer cells and evaluate the effect on cancer cell phenotypes. 
Since EGFR levels were largely unaffected by ankyrin105 expression, the cancer cell properties 
were not analyzed. Cancer cells usually display a decrease in both cell-cell and cell-matrix 
attachment and apoptosis and an increase in metastasis and proliferation (Kim et al., 2011; 
Weiss and Ward, 1983). Thus, several other experiments can be carried out to test the cancer 
cell properties in ankyrin105-overexpressing cells, such as adhesion, apoptosis, migration and 
proliferation assays. These additional results may provide a better understanding of how 
ankyrin105 impacts signaling regulation and the tumorigenic properties in these cell lines. 
In this project, we did not observe an effect of ankyrin105 overexpression on EGFR 
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degradation and its downstream signaling. Based on the results of Ignatiuk et al. and this 
project, the effect of ankyrin105 might be cell type specific or RTK specific. Further 
experiments to study ankyrin105 effect on EGFR degradation need to be carried out in a larger 
variety of cell lines. A suitable cell line for this study should express little or no endogenous 
ankyrin105 and ErbB2 and express high endogenous EGFR that can be degraded in response to 
EGF stimulation. When introducing ankyrin105 into cells, we need to consider that the gene 
delivery process may impact internalization, endocytosis and intracellular signaling pathways. 
So a method that minimizes this impact and expresses high levels of the ankyrin105 protein 
needs to be selected. For example, stable cell lines expressing ankyrin105 can be generated well 
after transfection or transduction. If differential effects on degradation kinetics of EGFR are 
observed, we could characterize the different mechanisms during EGFR endocytosis (e.g. 
clathrin-dependent or caveolae-dependent) to understand how ankyrin105 takes part in the 
receptor degradation process. We can also introduce EGFR into NIH 3T3 cells since NIH 3T3 
doesn’t express EGFR, and then test whether ankyrin105 overexpression has the same effect on 
EGFR degradation as previously shown for PDGFR degradation. 
For AU565 cells, herceptin treatment experiments need to be repeated to confirm the 
preliminary results. We can also try different concentrations of herceptin with the combination 
of EGF to optimize experiment conditions. A time course of EGF stimulation in parental cells, 
cells transduced with Ad-GFP and Ad-GFP+HA-Ank105 can be carried out after herceptin 
treatment to assess whether ankyrin105 overexpression can further downregulate EGFR. 
Alternatively, it might be best to generate stable AU565+HA-Ank105 cell lines and then 
compare their behavior upon herceptin+/-EGF with the parental AU565 cells. 
5.5 Conclusion 
The overexpression of ankyrin105 did not enhance EGFR degradation or downregulation 
of EGFR downstream signaling (PI3K-Akt and Ras-MAPK pathways) in COS-1, HEK293T, 
MCF10A, MDA-MB-231 and AU565 cells. The transfection or transduction process might 
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affect internalization, endocytosis and intracellular signaling pathways. 
In AU565 cells, geldanamycin induced the internalization and degradation of ErbB2 while 
EGF did not facilitate ErbB2 downregulation or further improve geldanamycin-induced ErbB2 
downregulation. EGFRs were also degraded in response to geldanamycin treatment. 
Ankyrin105 overexpression did not impact EGFR degradation or its downstream signaling 
pathways in geldanamycin-treated cells. Herceptin induced a small amount of internalization 
and degradation of ErbB2. EGF did not have an effect on ErbB2 internalization in combination 
with herceptin, but further promoted herceptin-induced ErbB2 downregulation. EGFRs were 
degraded when incubated with herceptin, EGF or herceptin+EGF, but degraded to a higher 
extent with herceptin+EGF treatment. 
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